View Filing Data

Print Document View Excel Document

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2012	Feb. 28, 2013	Jun. 30, 2012
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2012
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2012
Entity Registrant Name	Stereotaxis, Inc.
Entity Central Index Key	0001289340
Current Fiscal Year End Date	--12-31
Trading Symbol	stxs
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,063,239
Entity Public Float			$ 8,000,000

Balance Sheets - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Assets
Cash and cash equivalents	$ 7,777,718	$ 13,954,919
Accounts receivable, net of allowance of $640,183 and $667,529 in 2012 and 2011, respectively	11,551,651	11,104,038
Current portion of long-term receivables	18,838	59,679
Inventories	5,098,241	6,036,051
Prepaid expenses and other current assets	3,492,067	3,081,484
Total current assets	27,938,515	34,236,171
Property and equipment, net	2,141,923	3,323,856
Intangible assets, net	1,979,320	2,279,153
Long-term receivables	73,199	51,892
Other assets	32,987	40,760
Total assets	32,165,944	39,931,832
Liabilities and stockholders' deficit
Short-term debt and current maturities of long-term debt	12,264,490	21,173,321
Accounts payable	3,556,688	5,610,181
Accrued liabilities	5,361,810	5,703,166
Deferred revenue	9,502,939	8,220,306
Warrants and debt conversion features	2,968,348	125,415
Total current liabilities	33,654,275	40,832,389
Long-term debt, less current maturities	16,824,736	17,290,531
Long-term deferred revenue	477,159	634,713
Other liabilities		3,094
Stockholders' deficit:
Preferred stock, par value $0.001; 10,000,000 shares authorized, none outstanding at 2012 and 2011
Common stock, par value $0.001; 300,000,000 shares authorized, 8,018,615 and 5,543,157 shares issued at 2012 and 2011, respectively	8,019	5,543
Additional paid in capital	366,053,627	356,779,007
Treasury stock, 4,015 shares at 2012 and 2011	(205,999)	(205,999)
Accumulated deficit	(384,645,873)	(375,407,446)
Total stockholders' deficit	(18,790,226)	(18,828,895)
Total liabilities and stockholders' deficit	$ 32,165,944	$ 39,931,832

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Balance Sheets [Abstract]
Accounts receivable, allowance	$ 640,183	$ 667,529
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000
Common stock, shares issued	8,018,615	5,543,157
Treasury stock, shares	4,015	4,015

Statements Of Operations - USD ($)	12 Months Ended
Statements Of Operations - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenue:
Systems	$ 19,672,983	$ 15,585,538	$ 31,120,034
Disposables, service and accessories	26,889,451	26,401,894	22,931,203
Total revenue	46,562,434	41,987,432	54,051,237
Cost of revenue:
Systems	9,905,528	8,576,283	12,719,200
Disposables, service and accessories	4,875,527	3,921,798	2,845,487
Total cost of revenue	14,781,055	12,498,081	15,564,687
Gross margin	31,781,379	29,489,351	38,486,550
Operating expenses:
Research and development	8,405,086	12,886,488	12,244,163
Sales and marketing	20,607,999	31,635,415	30,178,818
General and administrative	13,394,556	16,908,656	15,022,689
Total operating expenses	42,407,641	61,430,559	57,445,670
Operating loss	(10,626,262)	(31,941,208)	(18,959,120)
Other income (expense)	8,265,507	3,416,383	2,060,346
Interest income	7,361	9,052	10,578
Interest expense	(6,885,033)	(3,515,402)	(3,035,291)
Net loss	$ (9,238,427)	$ (32,031,175)	$ (19,923,487)
Net earnings (loss) per common share:
Basic	$ (1.33)	$ (5.84)	$ (3.94)
Diluted	$ (1.33)	$ (5.84)	$ (3.94)
Weighted average shares used in computing net earnings (loss) per common share:
Basic	6,944,928	5,482,627	5,052,200
Diluted	6,944,928	5,482,627	5,052,200

Statement of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2009	$ 5,021	$ 331,295,105	$ (205,999)	$ (323,452,784)	$ 7,641,343
Shares, issued, beginning balance at Dec. 31, 2009	5,020,817
Issuance of common stock and warrants, value	$ 489	20,037,017			20,037,506
Issuance of common stock and warrants, shares	489,158
Share-based compensation, value		2,049,606			2,049,606
Issuance of stock under purchase plan, value	$ 6	209,772			209,778
Issuance of stock under purchase plan, shares	5,476
Exercise of stock options, value	$ 13	460,487			460,500
Exercise of stock options, shares	13,056
Grant of restricted shares, net of forfeitures, value	$ (54)	54
Grant of restricted shares, net of forfeitures, shares	(53,883)
Net Loss				(19,923,487)	(19,923,487)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2010	$ 5,475	354,052,041	(205,999)	(343,376,271)	10,475,246
Shares, issued, ending balance at Dec. 31, 2010	5,474,624
Issuance of common stock and warrants, value	$ 8	(8)
Issuance of common stock and warrants, shares	8,400
Share-based compensation, value		2,487,441			2,487,441
Issuance of stock under purchase plan, value	$ 9	232,382			232,391
Issuance of stock under purchase plan, shares	8,449
Exercise of stock options, value		7,202			7,202
Exercise of stock options, shares	468
Grant of restricted shares, net of forfeitures, value	$ 51	(51)
Grant of restricted shares, net of forfeitures, shares	51,216
Net Loss				(32,031,175)	(32,031,175)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2011	$ 5,543	356,779,007	(205,999)	(375,407,446)	(18,828,895)
Shares, issued, ending balance at Dec. 31, 2011	5,543,157
Issuance of common stock and warrants, value	$ 2,415	10,409,260			10,411,675
Issuance of common stock and warrants, shares	2,415,339
Share-based compensation, value		2,293,731			2,293,731
Issuance of stock under purchase plan, value	$ 10	73,543			73,553
Issuance of stock under purchase plan, shares	10,315
Exercise of stock options, value					$ 0
Exercise of stock options, shares					0
Grant of restricted shares, net of forfeitures, value	$ 20	(20)
Grant of restricted shares, net of forfeitures, shares	19,885
Restricted stock vestings, value	$ 31	(31)
Restricted stock vestings, shares	29,919
Reclass of warrants to liability		(3,501,863)			$ (3,501,863)
Net Loss				(9,238,427)	(9,238,427)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2012	$ 8,019	$ 366,053,627	$ (205,999)	$ (384,645,873)	$ (18,790,226)
Shares, issued, ending balance at Dec. 31, 2012	8,018,615

Statements Of Cash Flows - USD ($)	12 Months Ended
Statements Of Cash Flows - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Cash flows from operating activities
Net loss	$ (9,238,427)	$ (32,031,175)	$ (19,923,487)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	1,300,188	1,462,238	1,697,694
Amortization	299,833	299,833	230,459
Amortization of warrants	2,977,119	1,331,549	1,652,672
Share-based compensation, value	2,293,731	2,487,441	2,049,606
Non-cash royalty (income), net		(2,353,718)	(3,381,424)
Gain/loss on debt conversion	(75,612)
Loss on asset disposal	12,444	86,278	5,039
Adjustment of warrants and debt conversion features	(8,189,895)	(3,416,383)	(600,816)
Interest due from issuance of stock	192,128
Changes in operating assets and liabilities:
Accounts receivable	(447,613)	2,811,531	(2,762,921)
Other receivables	19,534	28,495	65,175
Inventories	937,810	(594,576)	(1,075,075)
Prepaid expenses and other current assets	(760,474)	827,297	522,924
Other assets	7,773	(2,223)	(33,426)
Accounts payable	(2,053,493)	(3,186,001)	4,937,129
Accrued liabilities	(514,689)	(1,090,072)	(1,221,120)
Deferred revenue	1,125,079	1,775,856	(1,060,903)
Other liabilities	(3,094)	(5,648)	(11,271)
Net cash used in operating activities	(12,117,658)	(31,569,278)	(18,909,745)
Cash flows from investing activities
Purchase of equipment	(130,699)	(1,031,749)	(715,770)
Net cash used in investing activities	(130,699)	(1,031,749)	(715,770)
Cash flows from financing activities
Proceeds from term note			10,000,000
Payments of term note	(4,000,000)	(2,000,000)	(333,333)
Proceeds from revolving line of credit	54,806,154	77,109,376	58,034,809
Payments of revolving line of credit	(62,842,934)	(72,818,866)	(57,503,298)
Proceeds from convertible debt	7,738,351
Proceeds/Payments from Healthcare Royalty Partners debt	2,500,000	14,317,397
Payments of Healthcare Royalty Partners debt	(1,252,647)
Payments of Biosense Debt		(5,540,373)	(2,071,139)
Proceeds from issuance of stock and warrants, net of issuance costs	9,122,232	239,593	16,200,745
Net cash provided by financing activities	6,071,156	11,307,127	24,327,784
Net decrease in cash and cash equivalents	(6,177,201)	(21,293,900)	4,702,269
Cash and cash equivalents at beginning of period	13,954,919	35,248,819	30,546,550
Cash and cash equivalents at end of period	7,777,718	13,954,919	35,248,819
Supplemental disclosures of cash flow information
Interest Paid	$ 3,258,900	$ 859,494	$ 140,253

Description Of Business	12 Months Ended
Description Of Business	Dec. 31, 2012
Description Of Business [Abstract]
Description Of Business	1. Description of Business Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (“Niobe ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive Robotic Navigation System (“Vdrive system”). The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema, which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training. Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop circular catheter manipulator is currently in human clinical trials and the V-Sono ICE Catheter Manipulator is under regulatory review by the U.S. Food and Drug Administration. Since our inception, we have generated significant losses. As of December 31 2012, we had incurred cumulative net losses of approximately $385 million. In May 2011, the Company introduced the Niobe ES system, which is the latest generation of the Niobe Robotic Magnetic Navigation System and will replace the Niobe II system going forward. Due to the fact that the Niobe ES system and upgrades from Niobe II to Niobe ES systems were not available to customers until December 2011, the product change created a rapid shift away from sales of the current Niobe II system, resulting in lower System Revenue in 2011. As of December 31, 2012, the Company had an installed base of 74 Niobe ES systems and has received positive feedback from the physicians at these sites. During the third quarter of 2011, the Company implemented a wide ranging plan to rebalance and reduce operating expenses by 15% to 20% on an annual run rate basis. During the year ended December 31, 2012, the Company reduced operating expenses by approximately $19 million or 31% over the prior year. We expect to incur additional losses into 2013 as we continue the development and commercialization of our products, conduct our research and development activities and advance new products into clinical development from our existing research programs and fund additional sales and marketing initiatives.

Summary Of Significant Accounting Policies	12 Months Ended
Summary Of Significant Accounting Policies	Dec. 31, 2012
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2012 or 2011. Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators. Financial Instruments Financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The Company’s financial assets consist of cash equivalents invested in money market funds and an embedded derivative associated with the convertible debt. The Company had cash equivalents invested in money market funds in the amount of $256,702 and $55,629 at December 31, 2012 and 2011, respectively. The financial assets consisting of cash equivalents invested in money market funds are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during the year ended December 31, 2012 and 2011, respectively. The Company’s embedded derivative asset associated with the convertible debt was $1,736 at December 31, 2012. This asset is classified as Level 3 as described above and is measured using the Black-Scholes valuation model. The mark-to-market adjustment recorded in other income for the derivative asset was $16,772 during the year ended December 31, 2012. There were no significant purchases, sales, settlements or issuances of Level 3 investments during the year. The embedded derivative was transferred into Level 3 in May 2012 at the time of issuance of the convertible debt. The Company’s financial liabilities consist of warrants and an embedded derivative associated with the convertible debt in the amount of $2,968,348 and $125,415 at December 31, 2012 and 2011, respectively. These liabilities are classified as Level 3 as described above and are measured using the Black-Scholes and Monte Carlo valuation models. The mark-to-market adjustment recorded in other income for these liabilities was $8,183,024 and $3,416,383 during the years ended December 31, 2012 and 2011, respectively. There was $23,643 of settlements of Level 3 investments during the year ended December 31, 2012. There were no purchases, sales, or issuances of Level 3 investments during the year. The warrants and embedded derivative were transferred into Level 3 at the time of issuance of the convertible debt, equity, and associated warrants. See Note 12 for additional details. Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items. Property and Equipment Property and equipment consist primarily of computer, office, and research and demonstration equipment held for lease and leasehold improvements and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years. Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value. Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates. Revenue and Costs of Revenue The Company adopted Accounting Standards Update 2009-13, Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) in the fourth quarter of 2009, effective as of January 1, 2009. Prior to the adoption of this guidance, the Company followed previously issued guidance for general accounting principles for revenue arrangements with multiple deliverables. Under this previously issued guidance, we were required to continually evaluate whether we had proper evidence to identify separate units of accounting for deliverables within certain contractual arrangements with customers. If we were unable to support the determination of vendor-specific objective evidence (“VSOE”) or third party evidence (“TPE”) of fair value on the undelivered element, we could not recognize revenue for the delivered elements. ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish VSOE or TPE. This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The adoption of the new guidance did not materially impact revenue reported in prior periods. The Company believes that the new guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy before and after the adoption of ASU 2009-13, a portion of revenue for the Niobe, Odyssey Vision, Odyssey Cinema, and Vdrive systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Beginning in the quarter ended March 31, 2010, revenue for Odyssey Vision Standard HD systems was recognized upon delivery due to the fact that third parties became qualified to perform installations. However, this change did not have a material impact on revenue recognition for the year ended December 31, 2010. Beginning in the quarter ended June 30, 2010, revenue for Odyssey Vision Quad systems was recognized upon delivery due to the fact that third parties became qualified to perform installations. This change resulted in additional revenue of $2.6 million and additional gross margin of $1.3 million during the year ended December 31, 2010. Beginning in the quarter ended December 31, 2010, revenue for Odyssey Cinema systems was recognized upon delivery due to the fact that third parties became qualified to perform installations. This change resulted in additional revenue of $0.7 million and additional $0.4 million in gross margin. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. However, the Company may deliver systems to a non-hospital site at the customer’s request as outlined in the terms and conditions of the sales agreement, in which case the Company evaluates whether the substance of the transaction meets the delivery and performance requirements for revenue recognition under “bill and hold” guidance. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic alliances under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned. Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date. The Company utilizes the Black-Scholes valuation model to determine the fair value of share-based payments at the date of grant with the following inputs: 1) expected dividend rate of 0%; 2) expected volatility of 50-151% based on the Company’s historical volatility; 3) risk-free interest rate based on the Treasury yield on the date of grant and; 4) expected term for grants using the simplified method which results in an expected term ranging from 3.75 to 6.25 years. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Net Loss per Common Share Basic loss per common share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the loss for the period by the weighted average number of common and common equivalent shares outstanding during the period. In addition, the application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable because the Company’s unearned restricted shares do not contractually participate in its losses. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. On July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock. The net loss per common share, shares outstanding, and weighted average shares outstanding reported in the financial statements and notes to the financial statements for the periods ending December 31, 2012, 2011, and 2010 are presented on a post-split basis. See Note 11 for additional discussion of the reverse stock split. As of December 31, 2012, the Company had 373,899 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $43.90 per share and 6,099,476 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $9.98 per share. The Company had a weighted average of 99,087 unearned restricted shares outstanding for the period ended December 31, 2012. Income Taxes In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized. Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate. Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. One customer, Siemens AG, Medical Solutions, and its affiliated entities, as our distributor, accounted for $2,452,034, $1,899,158, and $6,074,479, or 5%, 5%, and 11% of total net revenue for the years ended December 31, 2012, 2011, and 2010, respectively. No single customer accounted for more than 10% of total revenue for the year ended December 31, 2012. Reclassifications Common stock and additional paid-in capital in the prior year’s financial statements have been reclassified to reflect the one-for-ten reverse stock split effected on July 10, 2012. Refer to Note 11 for additional discussion of the reverse stock split. Recently Issued Accounting Pronouncements In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU” or “Update”) 2013-02, “Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (“AOCI”). The update requires that the Company present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of AOCI based on its source and the income statement line items affected by the reclassification. The guidance is effective for interim and annual reporting periods beginning on or after December 15, 2012. As the Company has no items of other comprehensive income, the Company is not required to report accumulated other comprehensive income. In December 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2011-11, “Disclosures about Offsetting Assets and Liabilities.” The Update enhances the disclosure of offsetting assets and liabilities by requiring companies to disclose both the gross and net information about instruments and transactions eligible for offset as well as those subject to an agreement similar to master netting arrangements. This guidance is effective for the Company’s interim and annual periods beginning January 1, 2013. The adoption of this pronouncement did not have an impact on the financial statements. In June 2011, the FASB issued new accounting guidance related to the presentation of comprehensive income that increases comparability between U.S. GAAP and International Financial Reporting Standards (“IFRS”). This guidance eliminates the current option to report other comprehensive income (OCI) and its components in the statement of changes in stockholders’ equity. This guidance was effective for the Company’s interim and annual periods beginning January 1, 2012. As the Company has no items of other comprehensive income, the Company is not required to report comprehensive income or other comprehensive income. In May 2011, the FASB issued Accounting Standards Update No. 2011-04, “Fair Value Measurement: Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS.” The Update amends the guidance on fair value measurements to develop common requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. GAAP and IFRS. The Update does not require additional fair value measurements and is not intended to establish valuation standards or affect valuation practices outside of financial reporting. This guidance was effective during interim and annual periods beginning after December 15, 2011. The adoption of this ASU did not have a material effect on our financial position or results of operations. In January 2010, the FASB issued Accounting Standards Update 2010-06 (“ASU 2010-06”), which is an amendment to the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification. This amendment requires disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures about the level of disaggregation and about inputs and valuation techniques used to measure fair value. This amendment is effective for periods beginning after December 15, 2009, except for the requirement to provide the Level 3 activity of purchases, sales, issuances, and settlements, which is effective for fiscal years beginning after December 15, 2010. See “Financial Instruments” section of Note 2 for required disclosures. Effective October 1, 2009, the Company adopted ASU 2009-13. ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. The Company adopted this standard in the fourth quarter of 2009, with retrospective application to January 1, 2009. The Company’s adoption of ASU 2009-13 did not have a material impact on any amounts previously reported for the first three quarters of 2009. The fourth quarter of 2009 was the first period during which we sold a Niobe^® system with an uninstalled Odyssey Enterprise Cinema system. Due to the fact that we had not established VSOE or TPE for uninstalled Odyssey Enterprise Cinema systems under the previous guidance, we would not have been able to recognize revenue for any portion of these transactions, which amounted to $2.0 million in revenue and $1.3 million in gross margin. Under the new guidance, we were able to use management’s estimate of selling price to establish new elements, including the Odyssey Enterprise Cinema, and recognize revenue for the delivered elements that were included in bundled transactions with these undelivered elements. The Company believes that the new guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances.

Inventory

12 Months Ended

Dec. 31, 2012

Inventory [Abstract]

Inventory

3. Inventory

Inventory consists of the following:


	December 31,	December 31,
	2012	2011

Raw materials	$ 3,303,053	$ 2,264,603
Work in process	65,546	131,980
Finished goods	1,802,281	3,790,625
Reserve for obsolescence	(72,639)	(151,157)
Total inventory	$ 5,098,241	$ 6,036,051

Prepaid Expenses And Other Current Assets

12 Months Ended

Dec. 31, 2012

Prepaid Expenses And Other Current Assets [Abstract]

Prepaid Expenses And Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:



	December 31, 2012	December 31, 2011

Prepaid expenses	$ 330,756	$ 460,297
Deferred cost of revenue	527,725	289,312
Derivative asset	1,736	-
Deferred Financing	1,590,916	1,647,435
Other assets	1,040,934	684,440
Total prepaid expenses and other current assets	$ 3,492,067	$ 3,081,484

Deferred cost of revenue represents the cost of systems for which title has transferred from the Company but for which revenue has not been recognized.

The derivative asset represents the fair value of a debt conversion feature that is part of the subordinated convertible debentures agreement. Refer to Notes 9 and 12 for discussion of the debentures and fair value measurement, respectively.

Property And Equipment

12 Months Ended

Dec. 31, 2012

Property And Equipment [Abstract]

Property And Equipment

5. Property and Equipment

Property and equipment consist of the following:


	December 31,	December 31,
	2012	2011

Equipment	$ 8,762,041	$ 8,977,623
Equipment held for lease	303,412	547,416
Leasehold improvements	2,328,381	2,473,880
	11,393,834	11,998,919
Less: Accumulated depreciation	(9,251,911)	(8,675,063)
Net property and equipment	$ 2,141,923	$ 3,323,856

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2012
Intangible Assets [Abstract]
Intangible Assets	6. Intangible Assets On June 4, 2010, the Company entered into an agreement to issue 45,000 shares of its common stock to a consultant (the “Purchaser”) in exchange for intellectual property rights related to the Company’s products. The Company issued 20,000 shares upon execution of the agreement and will issue an aggregate of 25,000 shares in annual installments on the first three anniversaries of the agreement. The unissued shares meet the criteria for equity classification under Accounting Standards Codification (ASC) 480 Distinguishing Liabilities from Equity and therefore are recorded in additional paid-in capital. There was no cash consideration paid for the securities. The securities were issued in consideration of the assignment to the Company of the Purchaser’s rights in certain intellectual property, including patent applications, in all inventions and discoveries in the Company’s business field (as defined in the agreement) that had been developed under various other agreements, which were terminated. The securities were sold by the Company in a private placement exempt from registration under Section 4(2) of the Securities Act of 1933 and Regulation D promulgated thereunder. There were no underwriters or placement agents involved in the transaction. As of December 31, 2012 and 2011, the Company had total intangible assets, including those described above, of $3.7 million. Accumulated amortization at December 31, 2012 and 2011, was $1,685,681 and 1,385,849. Amortization expense was $299,833, $299,833, and $230,459, in 2012, 2011, and 2010, respectively, as determined under the straight-line method. The estimated future amortization of intangible assets is $299,833 annually through July 2018, decreasing thereafter to $166,500 annually through May 2020

Accrued Liabilities

12 Months Ended

Dec. 31, 2012

Accrued Liabilities [Abstract]

Accrued Liabilities

7. Accrued Liabilities

Accrued liabilities consist of the following:


	December 31,	December 31,
	2012	2011

Accrued salaries, bonus, and benefits	$ 2,123,167	$ 3,229,382
Accrued research and development	89,654	27,044
Accrued legal and other professional fees	219,000	25,000
Other	2,929,989	2,421,740
Total accrued liabilities	$ 5,361,810	$ 5,703,166

Deferred Revenue

12 Months Ended

Dec. 31, 2012

Deferred Revenue [Abstract]

Deferred Revenue

8. Deferred Revenue

Deferred revenue consists of the following:


	December 31,	December 31,
	2012	2011

Product shipped, revenue deferred	$ 3,206,641	$ 2,001,160
Customer deposits	558,227	1,156,900
Deferred service and license fees	6,215,230	5,696,959
	9,980,098	8,855,019
Less: Long-term deferred revenue	(477,159)	(634,713)
Total current deferred revenue	$ 9,502,939	$ 8,220,306

Long-Term Debt And Credit Facilities

12 Months Ended

Dec. 31, 2012

Long-Term Debt And Credit Facilities [Abstract]

Long-Term Debt And Credit Facilities

9. Long-Term Debt and Credit Facilities

Debt outstanding consists of the following:

	December 31, 2012		December 31, 2011
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Revolving line of credit, due June 2013	$ 7,253,017	$ 7,277,084	$ 15,290,510	$ 15,371,063
Term note, due December 2013	4,000,000	4,000,000	8,000,000	8,000,000
Healthcare Royalty Partners debt	16,248,075	16,248,075	15,173,342	15,173,342
Subordinated convertible debentures	1,588,134	1,588,134	-	-
Total debt	29,089,226	29,113,293	38,463,852	38,544,405
Less current maturities	(12,264,490)	(12,288,557)	(21,173,321)	(21,253,874)
Total long term debt	$ 16,824,736	$ 16,824,736	$ 17,290,531	$ 17,290,531

Contractual principal maturities of debt at December 31, 2012 are as follows:


2013	$	12,264,490
2014⁽¹⁾		10,097,285
2015		2,312,052
2016		2,710,351
2017		3,177,265
2018 and Beyond		5,064,649
	$	35,626,092	⁽²⁾

(1) Includes $6.5 million convertible debt discount related to debt maturing on May 7, 2014.
(2) Future principal payments of Biosense Webster advance based on estimated future royalties.

Revolving line of credit

In November 2010, the Company received from affiliates of two members of our board of directors (“the Lenders”) an extension of their commitment to provide $10 million in either direct loans to the Company or loan guarantees to the Company’s primary bank lender through the earlier of March 31, 2012 or the date the Company receives $30 million of third party, non-bank financing, coincidental with the proposed maturity of the bank line of credit, as amended. The Company granted to the Lenders warrants to purchase 80,000 shares in exchange for their extension. The warrants are exercisable at $40.15 per share, beginning on March 1, 2011 and expiring on February 28, 2016. The fair value of these warrants of $1,747,392, calculated using the Black-Scholes method, will be deferred and amortized to interest expense ratably. As the previous guarantee was no longer in effect, the Company expensed in 2010 the entire balance on the warrants issued to the Lenders in October 2009.

In December 2010, the Company further amended its agreement with its primary lender to extend the maturity of the current working capital line of credit from March 31, 2011 to March 31, 2012, retaining the $30 million total availability under the line per the 2009 amendment. The revised agreement retained the $10 million sublimit for borrowings supported by guarantees from stockholders who at the time were affiliates of two members of its board of directors (“Lenders”) and considered to be related parties. Under the revised facility the Company is required to maintain a minimum “tangible net worth” and liquidity ratio as defined in the agreement. Interest on the facility accrued at the rate of prime plus 0.5% subject to a floor of 6% for the amount under guarantee and prime plus 1.75% subject to a floor of 7% for the remaining amounts.

In September 2011, the Company amended its agreement with its primary lender. The amendment reduced the availability amount of all credit extensions, other than the term loan, from $30 million to $20 million, and modified the interest rate applicable to the term loan from the lender’s prime rate plus 3.5% to the lender’s prime rate plus 5.5%.

On November 30, 2011, the Company entered into a Second Amended and Restated Loan and Security Agreement with its primary lender (“Amended Loan Agreement”). Under the Amended Loan Agreement, the Company agreed to revised tangible net worth and liquidity ratio covenants. Further, certain intellectual property assets of the Company were added to the collateral which secures repayment of the loan. Finally, the Amended Loan Agreement permits the Company to repay Healthcare Royalty Partners II, L.P. (formerly “Cowen Healthcare Royalty Partners II, L.P.”) under the Agreement with the royalties due to the Company under the Biosense Agreement (the "Biosense Agreement"), as described below.

On March 30, 2012, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from March 31, 2012 to April 30, 2012 and reduced the Company’s borrowing availability by $3,333,333. The Company also extended until April 30, 2012 the $10 million guarantee provided by the Lenders. As a result of this extension, the Company issued the Lenders warrants to purchase 75,735 shares of common stock at $6.60 per share.

On May 1, 2012, the Company and its primary lender entered into an agreement in which the lender extended the maturity of the revolving line of credit from April 30, 2012 to May 15, 2012. The Company also amended its agreement with the Lenders to extend the $10 million loan guarantee through May 15, 2012. The Company granted warrants to purchase an aggregate of 60,976 shares of common stock in exchange for the extension of the guarantee.

On May 10, 2012, upon closing of financing transactions for gross proceeds of $18.5 million, the Company entered into the Third Loan Modification Agreement with its primary lender. The amendment extended the revolving credit facility maturity to March 31, 2013 and revised the financial covenants. Additionally, the revolving line of credit was decreased from $20 million to $13 million. The reduction was as result of the pay down of $7 million of the guarantees provided by the Lenders.

As of December 31, 2012, the Company had $7.3 million outstanding under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of December 31, 2012, the Company had a borrowing capacity of $7.7 million based on the Company’s collateralized assets, including amounts already drawn. As such, the Company had the ability to borrow an additional $0.4 million under the revolving line of credit at December 31, 2012. As of December 31, 2012, the Company was in compliance with all covenants of the bank loan agreement and had no remaining availability on its Lender loan and guarantee.

On March 29, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from March 31, 2013 to June 30, 2013. The company also extended until June 30, 2013 the $3 million guarantee by the Lenders. As a result of this extension, the Company issued the Lenders warrants to purchase 113,636 shares of common stock at $1.98 per share.

The revolving line of credit and the Company’s term notes (collectively, the “Credit Agreements”) are secured by substantially all of the Company’s assets. The Company is also required under the Credit Agreements to maintain its primary operating account and the majority of its cash and investment balances in accounts with the primary lender.

Term note

In June 2007, the Company entered into a term note due in June 2010 with its primary lender for $2,000,000. The Company was required to make equal payments of principal and interest, at prime plus 1%, through June 2010, at which time the term note matured.

Under the 2010 amendment to the loan agreement, the Company entered into a $10 million term loan maturing on December 31, 2013, with $2 million of principal due in 2011 and $4 million of principal due in each of 2012 and 2013. Interest on the term loan accrued at the rate of prime plus 3.5%. Under this agreement, the Company provided its primary lender with warrants to purchase 11,111 shares of common stock. The warrants are exercisable at $36.00 per share, beginning on December 17, 2010 and expiring on December 17, 2015. The fair value of these warrants of $228,332, calculated using the Black-Scholes method, will be deferred and amortized to interest expense ratably over the life of the term loan.

On September 30, 2011, we entered into a fourth loan modification agreement with our primary lender which modifies the interest rate applicable to the term loan under the Original Agreement from the Lender’s prime rate plus 3.5% to the Bank’s prime rate plus 5.5%.

Healthcare Royalty Partners Debt

In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners II, L.P. (formerly “Healthcare Royalty Partners II, L.P.”). Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the nine months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the twelve months ended December 31, 2012. The loan will be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe system in cardiac ablation procedures. Under the terms of the Agreement, Healthcare Royalty Partners will be entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan is repaid. The loan is a full recourse loan, matures on December 31, 2018, and bears interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement are insufficient to pay all amounts of interest due on the loan, then such deficiency will increase the outstanding principal amount on the loan. After the loan obligation is repaid, the royalties under the Biosense Agreement will again be paid to the Company. The loan is also secured by certain assets and intellectual property of the Company. The Agreement also contains customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender under the Amended Loans Agreement described above.

Subordinated Convertible Debentures

In May 2012, the Company entered into a securities purchase agreement with certain institutional investors whereby the Company agreed to sell an aggregate of approximately $8.5 million in aggregate principal amount of unsecured, subordinated, convertible debentures (the “Debentures”), which became convertible into shares of the Company’s common stock at a conversion price of $3.361 per share (or approximately 2.5 million shares in the aggregate), on July 10, 2012, the date that the Company received shareholder approval for the transaction. The purchasers of the Debentures also received six-year warrants to purchase an aggregate of approximately 2.5 million shares of the Company’s common stock at an exercise price of $3.361 per share. The Debentures bear interest at 8% per year and mature on May 7, 2014. In addition, the Company has the ability to issue shares of its common stock in lieu of cash interest payments under certain circumstances, and intends to do so at such time as the Company has registered the shares for resale.

The Company recorded the Debentures on the balance sheet net of the debt discount of $7.5 million. The debt discount is due to warrants issued in conjunction with the Debentures and the debt conversion features. Upon issuance of the Debentures, the fair value of the warrants and derivative liability were $4.1 million and $3.5 million, respectively. The debt discount will be amortized over the life of the loan using the effective interest method and the warrants and derivative liability will be recorded at fair value on each reporting period. Refer to Note 12 for additional discussion of the fair value of the warrants and conversion features.

Biosense Webster Advance

In July 2008, the Company and Biosense Webster entered into an amendment to their existing agreements relating to the development and sale of catheters. Pursuant to the amendment, Biosense Webster agreed to pay to the Company $10.0 million as an advance on royalty amounts that were owed at the time the amendment was executed or would be owed in the future by Biosense Webster to the Company pursuant to the royalty provisions of one of the existing agreements. The Company and Biosense Webster also agreed that an aggregate of up to $8.0 million of certain agreed upon research and development expenses that were owed at the time the amendment was executed or may be owed in the future by the Company to Biosense Webster pursuant to the existing agreement would be deferred and would be due, together with any unrecouped portion of the $10.0 million royalty advance, no later than December 31, 2011. Interest on the outstanding and unrecouped amounts of the royalty advance and deferred research and development expenses accrued at an interest rate of the prime rate plus 0.75%. Outstanding royalty advances and deferred research and development expenses and accrued interest thereon were recouped by Biosense Webster by deductions from royalty amounts otherwise owed to the Company from Biosense Webster pursuant to the existing agreement. Approximately $18.0 million had been advanced by Biosense Webster to the Company pursuant to the amendment. As of December 31, 2011, these amounts plus interest accrued thereon had been repaid in full, in accordance with the agreement. The Company recorded research and development expenses of $0.4 million, $1.1 million, and $0.6 million, and disposables, service and accessories revenue of $3.2 million, $3.6 million, and $3.9 million for the years ended December 31, 2012, 2011, and 2010, respectively, related to this agreement.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Lease Obligations

12 Months Ended

Dec. 31, 2012

Lease Obligations [Abstract]

Lease Obligations

10. Lease Obligations

The Company leases its facilities under operating leases. For the years ended December 31, 2012, 2011, and 2010 rent expense was $1,697,153, $1,711,647, and $1,548,869, respectively.

In January 2006, the Company moved its primary operations into new facilities. The facility is subject to a lease which expires in 2018. Under the terms of the lease, the Company has options to renew for up to three additional years. The lease contains an escalating rent provision which the Company has straight-lined over the term of the lease.

The future minimum lease payments under non-cancelable leases as of December 31, 2012 are as follows:


		Operating
Year		Lease
2013	$	1,728,937
2014		1,731,904
2015		1,710,778
2016		2,194,791
2017		2,189,376
2018 and Beyond		2,186,668
Total minimum lease payments		11,742,454

- Definition

The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.

+ References + Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2012

Stockholders' Equity [Abstract]

Stockholders' Equity

11. Stockholders’ Equity

Public Offerings of Common Stock

In November 2010, we completed a public offering of our common stock in which we issued 460,000 shares at $36.50 per share and realized approximately $15.5 million in proceeds, net of fees and expenses.

In May 2012, the Company entered into a Stock and Warrant Purchase Agreement with certain institutional investors whereby it agreed to sell an aggregate of approximately 2.17 million shares of the Company's common stock (the “PIPE Common Stock”) at a price of $3.361 per share, together with six-year warrants at a price of $1.25 per share to purchase an aggregate of approximately 2.17 million shares of common stock having an exercise price of $3.361 per share (the “PIPE Warrants”). Each purchaser received a PIPE Warrant to purchase one share of common stock for every share of PIPE Common Stock purchased.

As described above, on July 10, 2012, the Company effected a one-for-ten Reverse Stock Split of the Company’s common stock. All figures reported within this document have been adjusted to reflect this reverse stock split.

Net proceeds from the sale of the securities were approximately $9.1 million, after placement agent fees and other offering expenses. The Company used the funds to repay $7 million of the revolving credit facility guaranteed by the Lenders and plans to use the balance for working capital and general corporate purposes.

The holders of common stock are entitled one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the our Revolving Credit Agreement. No dividends have been declared or paid as of December 31, 2012.

The Company has reserved shares of common stock for the exercise of warrants, the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows:


	December 31,	December 31,
	2012	2011
Warrants	6,099,476	1,038,161
Stock award plans	131,464	36,469
Employee Stock Purchase Plan	0	10,415
	6,230,940	1,085,045

Stock Award Plans

The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In August 2012, the Board of Directors adopted a stock incentive plan (the 2012 Stock Incentive Plan) which was subsequently approved by the Company’s stockholders. This plan replaces the 2002 Stock Incentive Plan which expired on March 25, 2012.

The 2012 Stock Incentive Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares and restricted share units to employees, directors, and consultants. Options granted under the 2012 Stock Incentive Plan expire no later than ten years from the date of grant. The exercise price of each incentive stock option shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. The vesting provisions of individual options may vary, but incentive stock options generally vest 25% on the first anniversary of each grant and 1/48 per month over the next three years. Stock appreciation rights are rights to acquire a calculated number of shares of the Company’s common stock upon exercise of the rights. The number of shares to be issued is calculated as the difference between the exercise price of the right and the aggregate market value of the underlying shares on the exercise date divided by the market value as of the exercise date. Stock appreciation rights granted under the 2012 Stock Incentive Plan generally vest 25% on the first anniversary of such grant and 1/48 per month over the next three years and expire no later than ten years from the date of grant. The Company generally issues new shares upon the exercise of stock options and stock appreciation rights.

Restricted share grants are either time-based or performance-based. Time-based restricted shares generally cliff vest three years after grant. Performance-based restricted shares vest upon the achievement of performance objectives which are determined by the Company’s Board of Directors.

Restricted stock unit grants are time-based and generally vest over a period of 18 months to four years. Options granted to non-employee directors expire no later than ten years from the date of grant. The exercise price of options to non-employee directors shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. Initial grants of options to new directors generally vest over a two year period. Annual grants to directors generally vest upon the earlier of one year or the next stockholder meeting.

A summary of the option and stock appreciation rights activity for the year ended December 31, 2012 is as follows:

	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2011	562,733	$10.00 - $125.50	$ 48.53
Granted	12,048	$1.63 - $8.10	$ 4.32
Exercised	-	$0.00 - $0.00	-
Forfeited	(200,882)	$1.69 - $125.50	$ 54.51
Outstanding, December 31, 2012	373,899	$1.63 - $116.40	$ 43.90

As of December 31, 2012, the weighted average remaining contractual life of the options and stock appreciation rights outstanding was 4.7 years. Of the 373,899 options and stock appreciation rights that were outstanding as of December 31, 2012, 267,149 were vested and exercisable with a weighted average exercise price of $49.13 per share and a weighted average remaining term of 4.0 years.

A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows:


	Year Ended December 31, 2012
							Number of		Weighted
			Weighted		Weighted		Options		Average Exercise
	Options		Average		Average		Currently		Price Per Vested
Range of Exercise Prices	Outstanding		Remaining Life		Exercise Price		Exercisable		Share
$1.00 - $20.00		30,147		8.87 years	$	8.33		7,275	$	10.39
$20.01 - $50.00		264,239		5.04 years	$	38.79		180,383	$	39.53
$50.01 - $100.00		67,863		2.22 years	$	68.00		67,841	$	68.00
$100.01 - $150.00		11,650		3.78 years	$	112.05		11,650	$	112.05
		373,899		4.7 years	$	43.90		267,149	$	49.13

The intrinsic value of options and stock appreciation rights is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options and stock appreciation rights that were in-the-money at December 31, 2012. As of December 31, 2012, 6,125 options and stock appreciation rights were in-the-money. The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2012 was approximately $5,298 based on a closing share price of $2.55 on December 31, 2012. There were no fully vested options and stock appreciation rights outstanding at December 31, 2012. During the year ended December 31, 2012, no options or stock appreciation rights were exercised under the Company’s stock option. The weighted average grant date fair value of options and stock appreciation rights granted during the year ended December 31, 2012 was $4.32 per share.

During the year ended December 31, 2012 the Company realized $0 from the exercise of stock options and stock appreciation rights and less than $0.1 million and $0.5 million during 2011 and 2010, respectively.

A summary of the restricted share grant activity for the year ended December 31, 2012 is as follows:

	Number of Shares	Weighted Average Grant Date Fair Value per Share

Outstanding, December 31, 2011	52,659	$ 34.17
Granted	85,250	$ 8.00
Vested	(4,001)	$ 37.32
Forfeited	(65,365)	$ 14.05
Outstanding, December 31, 2012	68,543	$ 20.62

A summary of the restricted stock unit activity for the year ended December 31, 2012 is as follows:

	Number of Restricted Shares Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2011	98,820	$ 10.89
Granted	509,272	$ 1.89
Vested	(29,919)	$ 10.89
Forfeited	(48,861)	$ 6.51

Outstanding, December 31, 2012	529,312	$ 2.64

A summary of the restricted shares outstanding as of December 31, 2012 is as follows:

	Number of Shares

Time based restricted shares	9,458
Performance based restricted shares	59,085
Outstanding, December 31, 2012	68,543

The intrinsic value of restricted shares and restricted stock units outstanding at December 31, 2012 was approximately $0.1 million and $1.3 million, respectively, based on a closing share price of $2.55 as of December 31, 2012. During the year ended December 31, 2012, the aggregate intrinsic value of restricted shares and restricted stock units vested was approximately $0 and $0.1 million, respectively, determined at the date of vesting.

During the year ended December 31, 2012, the Company determined that it was not probable that the performance conditions related to certain of its outstanding restricted share awards would be achieved and accordingly, recorded approximately $(1.2) million as a cumulative catch-up adjustment resulting in a reduction of share based compensation. During the third quarter of 2011, the Company made an adjustment to its forfeiture rate based on historical information, which resulted in a reduction of share-based compensation of $(0.5) million for the year ended December 31, 2011.

As of December 31, 2012, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $5.9 million, net of estimated forfeitures of approximately $3.3 million. This cost will be amortized over a period of up to four years on a straight-line basis over the underlying estimated service periods and will be adjusted for subsequent changes in estimated forfeitures.

2009 Employee Stock Purchase Plan

In 2009, the Company adopted its 2009 Employee Stock Purchase Plan and reserved 25,000 shares of common stock for issuance pursuant to the plan. The Company offered employees the opportunity to participate in the plan beginning July 1, 2009 with an initial purchase date of September 30, 2009. Eligible employees had the opportunity to participate in a new purchase period every 3 months. Under the terms of the plan, employees could purchase up to 15% of their compensation of the Company’s common stock, subject to an annual maximum of $25,000, at 95% of the fair market value of the stock at the end of the purchase period, subject to certain plan limitations. As of December 31, 2012, a total of 24,901 shares had been purchased under this plan. As of December 31, 2012 there were no remaining shares available for issuance under the Employee Stock Purchase Plan as the plan was suspended in 2012.

Warrants

In November 2010, the Company issued warrants to purchase 80,000 shares of common stock in conjunction with the offering as discussed above in “Public Offerings of Common Stock.”

In December 2010, the Company issued warrants to purchase 11,111 shares of common stock in conjunction with the amendment of the loan agreement as described in Note 9.

During 2012, 2011, and 2010, warrants for 0, 0, and 0 shares, respectively, were exercised.

Reverse Stock Split

On July 10, 2012, the Company filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to implement a one-for-ten reverse split of our common stock (the “Reverse Stock Split”). The ratio for the Reverse Stock Split was determined by our Board of Directors pursuant to the approval of the stockholders at the Company’s special meeting of stockholders held on July 10, 2012, authorizing the Board to effect a reverse stock split within a range of one-for-four to one-for-ten shares of the Company’s common stock. The Reverse Stock Split was effective as of July 10, 2012, and the Company’s common stock began trading on the Nasdaq Global Market on a post-split basis on July 11, 2012.

As a result of the Reverse Stock Split, each ten shares of the Company’s issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock. The Reverse Stock Split affected all issued and outstanding shares of the Company’s common stock, as well as common stock underlying stock options, stock appreciation rights, restricted stock, restricted stock units, warrants and convertible debentures outstanding immediately prior to the effectiveness of the Reverse Stock Split. The Reverse Stock Split reduced the number of shares of the Company’s common stock outstanding from approximately 78 million to 7.8 million at the time of the Reverse Stock Split. In addition, the Amendment increased the number of authorized shares of the Company’s common stock from 100 million to 300 million. The Reverse Stock Split did not alter the par value of common stock, which remained $0.001 per share, or modify any voting rights or other terms of the Company’s common stock. Unless otherwise indicated, all information set forth herein gives effect to such Reverse Stock Split.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph d

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7, 11A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

+ Details

Fair Value Measurements

12 Months Ended

Dec. 31, 2012

Fair Value Measurements [Abstract]

Fair Value Measurements

12. Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below:

Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.

Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.

The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets at December 31, 2012:
Cash equivalents	$	256,702	256,702	—	—
Derivative asset		1,736	—	—	1,736
Total assets at fair value	$	258,438	256,702	—	1,736
Liabilities at December 31, 2012:
Warrants issued December 29, 2008	$	71,581	—	—	71,581
Warrants issued May 10, 2012		2,347,902	—	—	2,347,902
Derivative liability		548,865	—	—	548,865
Total liabilities at fair value:	$	2,968,348	—	—	2,968,348
Assets at December 31, 2011:
Cash equivalents	$	55,629	55,629	—	—
Total assets at fair value	$	55,629	55,629	—	—
Liabilities at December 31, 2011:
Warrants issued December 29, 2008	$	125,415	—	—	125,415
Total liabilities at fair value:	$	125,415	—	—	125,415

Level 1

The Company’s financial assets consist of cash equivalents invested in money market funds in the amount of $256,702 and $55,629 at December 31, 2012 and December 31, 2011, respectively. These assets are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during both the years ended December 31, 2012 and December 31, 2011. There were no transfers in or out of Level 1 during the year ended December 31, 2012.

Level 2

The Company does not have any financial assets or liabilities classified as Level 2.

Level 3

In conjunction with its December 29, 2008 registered direct offering, the Company issued warrants to purchase 179,241 shares of the Company’s common stock that contained a provision that required a reduction of the exercise price if certain equity events occurred. Under the provisions of general accounting principles for derivatives and hedging activities and determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, such a reset provision does not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations. General accounting principles for determining whether an instrument (or embedded feature) is indexed to an entity’s own stock became effective for the Company as of January 1, 2009. Accordingly, the fair value of the warrants as of that date was reclassified from stockholders’ equity into current liabilities.

In accordance with general accounting principles for fair value measurement, the Company’s warrants in the amount of $71,581 were measured at fair value on a recurring basis as of December 31, 2012 and were valued using Level 3 valuation inputs. A Black-Scholes model was used to value the Company’s warrants at December 31, 2012 using the following assumptions: 1) dividend yield of 0%; 2) volatility of 116.49%; 3) risk-free interest rate of 0.36%; and 4) expected life of 1.5 years.

In the Company’s May 2012 financing transaction, the Company issued subordinated convertible debentures and warrants. The optional conversion feature of the subordinated convertible debentures is classified as a derivative liability within “Warrants and derivative liabilities” on the Company’s balance sheet. The warrants issued in conjunction with the Debentures and PIPE are also considered a liability. Due to the provisions included in the warrant agreements, the warrants do not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The warrants and derivative liability are periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.

Per the terms of the Debentures agreement, the Company may require each holder to convert up to 50% of the Debentures if the common stock closes above $15.00, or 100% of the Debentures if the common stock closes above $20.00 (in each case, as adjusted for stock splits, recapitalizations and similar events) during a 20 consecutive trading day period and the resale registration statement has been declared effective by the SEC and is available for the issuance of the common stock upon conversion of the Debentures. In the event of any forced conversion by the Company, the minimum amount that the Company can force the holders to convert shall be $2.5 million of Debentures in the aggregate. This mandatory redemption clause is classified as a derivative asset within “Prepaid and other current assets” on the Company’s balance sheet. The derivative asset is periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.

In accordance with general accounting principles for fair value measurement, the Company’s warrants, derivative liability, and derivative asset were measured at fair value on a recurring basis as of December 31, 2012 and were valued using Level 3 valuation inputs. A Monte-Carlo simulation was used to value the derivative asset and liabilities upon issuance on May 10, 2012 using the following assumptions: 1) volatility of 80%; 2) risk-free interest rate of 1.035%; and 3) a closing stock price of $3.413. The derivative asset and liabilities were revalued as of December 31, 2012 using the following assumptions: 1) volatility of 85%; 2) risk-free interest rate of 0.802%; and 3) a closing stock price of $2.55.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial asset and liabilities for the year ended December 31, 2012:

	Derivative Asset	Total Assets	Warrants issued December 29, 2008	Warrants issued May 10, 2012		Derivative Liability		Total Liabilities
Balance at beginning of period⁽¹⁾	$ 18,508	$ 18,508	$ 125,415	$ 7,573,466	$ 3,476,134		$ 11,175,015
Settlements	-	-	-	-		(23,643)		(23,643)
Revaluation	(16,772)	(16,772)	(53,834)	(5,225,564)		(2,903,626)		(8,183,024)
Balance at end of period	$ 1,736	$ 1,736	$ 71,581	$ 2,347,902		$ 548,865		$ 2,968,348

⁽¹⁾The beginning of the period is December 31, 2011 for warrants issued December 29, 2008. The beginning of the period for the derivative asset, warrants issued May 10, 2012, and derivative liability is May 10, 2012.

The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2012

Income Taxes [Abstract]

Income Taxes

13. Income Taxes

The provision for income taxes consists of the following:


	Year Ended December 31,
	2012			2011			2010
Deferred:
Federal	$	4,586,506		$	11,367,771		$	5,650,309
State and local		493,946			1,437,062			464,169
		5,080,452			12,804,833			6,114,478
Valuation allowance		(5,080,452	)		(12,804,833	)		(6,114,478	)
	$	—		$	—		$	—

The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following:


	Year Ended December 31,
	2012		2011		2010
U.S. statutory income tax rate	34.0	%	34	%	34	%
State and local taxes, net of federal tax benefit	5.2	%	4.5	%	2.3	%
Permanent differences between book and tax and other	14.4	%	1.5	%	(5.6	)%
Valuation allowance	(53.6	)%	(40.0	)%	(30.7	)%
Effective income tax rate	0	%	0	%	0	%

In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable losses, and projections for future periods over which the deferred tax assets are deductible, the Company determined that a 100% valuation allowance of deferred tax assets was appropriate. The valuation allowance for deferred tax assets includes amounts for which subsequently recognized tax benefits will be applied directly to contributed capital.

The components of the deferred tax asset are as follows:


	December 31,
	2012			2011
Current accruals	$	1,753,064		$	1,751,515
Depreciation and amortization		2,676,884			2,644,059
Deferred compensation		5,332,415			4,648,719
Net operating loss carryovers		127,477,179			123,114,797
Deferred tax assets		137,239,542			132,159,090
Valuation allowance		(137,239,542	)		(132,159,090	)
Net deferred tax assets	$	—		$	—

As of December 31, 2012, we had federal net operating loss carryforwards of approximately $351.0 million. The federal net operating loss carryforwards will expire between 2018 and 2032. As of December 31, 2012, we had state net operating loss carryforwards of approximately $8.4 million which will expire at various dates between 2013 and 2031 if not utilized. Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We currently have a full valuation allowance against the deferred tax asset. Our ability to use these losses to offset future taxable income will be limited if we experience an “ownership change” as defined in Section 382 of the Code.

The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. As the Company has a federal Net Operating Loss carryforward from the year ended December 31, 1994 forward, all tax years from 1994 forward are subject to examination. As states have varying carryforward periods, and the Company has recently entered into additional states, the states are generally subject to examination for the previous 10 years or less.

The Company recognizes interest accrued, if any, net of tax and penalties, related to unrecognized tax benefits as components of income tax provision as applicable. As of December 31, 2012, accrued interest and penalties were not material.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Net Loss Per Share

12 Months Ended

Dec. 31, 2012

Net Loss Per Share [Abstract]

Net Loss Per Share

14. Net Loss per Share

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations:


	Year Ended December 31,
	2012		2011		2010
Numerator:
Numerator for basic EPS	$	(9,238,427)	$	(32,031,175)	$	(19,923,487)
Effect of dilutive securities:		—		—		—
Numerator for diluted EPS	$	(9,238,427)	$	(32,031,175)	$	(19,923,487)
Denominator:
Denominator for basic EPS—weighted average shares		6,944,928		5,482,627		5,052,200
Effect of dilutive securities:		—		—		—
Denominator for diluted EPS		6,944,928		5,482,627		5,052,200
Basic EPS	$	(1.33)	$	(5.84)	$	(3.94)
Diluted EPS	$	(1.33)	$	(5.84)	$	(3.94)

The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows:


	December 31,
	2012		2011		2010
Shares outstanding
Restricted shares		68,543		52,659		3,328
Shares issuable upon vesting/exercise of:
Options to purchase common stock		373,899		562,733		471,108
Restricted stock units		529,312		98,820		—
Warrants		6,099,476		1,038,161		1,038,161
		7,071,230		1,752,374		1,512,598

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2012
Empoyee Benefit Plan [Abstract]
Employee Benefit Plan	15. Employee Benefit Plan The Company offers employees the opportunity to participate in a 401(k) plan. Through September 30, 2011, the Company matched employee contributions dollar for dollar up to 3% of the employee’s salary during the employee’s period of participation. Such employer contributions are discretionary under the 401(k) plan. As of October 1, 2011, the Company suspended all matching contributions indefinitely. For the years ended December 31, 2012, 2011, and 2010, the Company expensed $8,595, $395,633, and $414,765, respectively, related to the plan.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph q
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 8
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-2
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 30
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 20, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Implementation Guide (Q and A)
-Number FAS88
-Paragraph 63
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

+ Details

Product Warranty Provisions

12 Months Ended

Dec. 31, 2012

Product Warranty Provisions [Abstract]

Product Warranty Provisions

16. Product Warranty Provisions

The Company’s standard policy is to warrant all Niobe and Odyssey systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.

Accrued warranty, which is included in other accrued liabilities, consists of the following:


	December 31, 2012		December 31, 2011
Warranty accrual, beginning of the fiscal year	$	691,832	$	469,837
Warranty expense incurred		650,367		762,872
Payments made		(688,726)		(540,877)
Warranty accrual, end of the fiscal year	$	653,473	$	691,832

Commitments And Contingencies	12 Months Ended
Commitments And Contingencies	Dec. 31, 2012
Commitments And Contingencies [Abstract]
Commitments And Contingencies	17. Commitments and Contingencies The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company. In 2012, the Company entered into a letter of credit to support a commitment in the amount of approximately $0.1 million. This letter of credit is valid through 2015.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Segment Information

12 Months Ended

Dec. 31, 2012

Segment Information [Abstract]

Segment Information

18. Segment Information

The Company considers reporting segments in accordance with general accounting principles for disclosures about segments of an enterprise and related information. The Company’s system and disposable devices are developed and marketed to a broad base of hospitals in the United States and internationally. The Company considers all such sales to be part of a single operating segment.


	Year Ended December 31,
	2012		2011		2010
United States	$	27,034,200	$	23,947,048	$	28,840,803
International		19,528,234		18,040,384		25,210,434
Total	$	46,562,434	$	41,987,432	$	54,051,237

All of the Company’s long-lived assets are located in the United States. Revenues are attributed to countries based on the location of the customer.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

+ Details

Quarterly Data (Unaudited)

12 Months Ended

Dec. 31, 2012

Quarterly Data (Unaudited) [Abstract]

Quarterly Data (Unaudited)

19. Quarterly Data (Unaudited)

The following tabulations reflect the unaudited quarterly results of operations for the years ended December 31, 2012 and 2011:



								Basic			Diluted
								Loss Per			Loss Per
	Net Sales		Gross Profit		Net Loss			Share			Share
2012
First quarter	$	12,283,228	$	8,521,397	$	(5,812,912	)	$	(1.06	)	$	(1.06	)
Second quarter		10,512,898		7,252,820		2,806,427			0.42			0.32
Third quarter		11,561,399		8,074,578		(1,915,281	)		(0.25	)		(0.25	)
Fourth quarter		12,204,910		7,932,584		(4,316,661	)		(0.55	)		(0.55	)
2011
First quarter	$	10,224,704	$	7,219,725	$	(9,549,933	)	$	(1.75	)	$	(1.75	)
Second quarter		11,602,139		8,085,793		(9,694,685	)		(1.77	)		(1.77	)
Third quarter		8,544,014		5,886,760		(7,273,070	)		(1.33	)		(1.33	)
Fourth quarter		11,616,575		8,297,073		(5,513,487	)		(1.00	)		(1.00	)

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2012
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events None other than as outlined in Note 9.

Summary Of Significant Accounting Policies (Policy)	12 Months Ended
Summary Of Significant Accounting Policies (Policy)	Dec. 31, 2012
Summary Of Significant Accounting Policies [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2012 or 2011.
Accounts Receivable and Allowance for Uncollectible Accounts	Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators.
Fair Value Measurements	Financial Instruments Financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The Company’s financial assets consist of cash equivalents invested in money market funds and an embedded derivative associated with the convertible debt. The Company had cash equivalents invested in money market funds in the amount of $256,702 and $55,629 at December 31, 2012 and 2011, respectively. The financial assets consisting of cash equivalents invested in money market funds are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during the year ended December 31, 2012 and 2011, respectively. The Company’s embedded derivative asset associated with the convertible debt was $1,736 at December 31, 2012. This asset is classified as Level 3 as described above and is measured using the Black-Scholes valuation model. The mark-to-market adjustment recorded in other income for the derivative asset was $16,772 during the year ended December 31, 2012. There were no significant purchases, sales, settlements or issuances of Level 3 investments during the year. The embedded derivative was transferred into Level 3 in May 2012 at the time of issuance of the convertible debt. The Company’s financial liabilities consist of warrants and an embedded derivative associated with the convertible debt in the amount of $2,968,348 and $125,415 at December 31, 2012 and 2011, respectively. These liabilities are classified as Level 3 as described above and are measured using the Black-Scholes and Monte Carlo valuation models. The mark-to-market adjustment recorded in other income for these liabilities was $8,183,024 and $3,416,383 during the years ended December 31, 2012 and 2011, respectively. There was $23,643 of settlements of Level 3 investments during the year ended December 31, 2012. There were no purchases, sales, or issuances of Level 3 investments during the year. The warrants and embedded derivative were transferred into Level 3 at the time of issuance of the convertible debt, equity, and associated warrants. See Note 12 for additional details.
Inventory	Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items.
Property and Equipment	Property and Equipment Property and equipment consist primarily of computer, office, and research and demonstration equipment held for lease and leasehold improvements and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years. Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value
Intangible Assets	Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.
Revenue and Costs Of Revenue	Revenue and Costs of Revenue The Company adopted Accounting Standards Update 2009-13, Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) in the fourth quarter of 2009, effective as of January 1, 2009. Prior to the adoption of this guidance, the Company followed previously issued guidance for general accounting principles for revenue arrangements with multiple deliverables. Under this previously issued guidance, we were required to continually evaluate whether we had proper evidence to identify separate units of accounting for deliverables within certain contractual arrangements with customers. If we were unable to support the determination of vendor-specific objective evidence (“VSOE”) or third party evidence (“TPE”) of fair value on the undelivered element, we could not recognize revenue for the delivered elements. ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish VSOE or TPE. This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The adoption of the new guidance did not materially impact revenue reported in prior periods. The Company believes that the new guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy before and after the adoption of ASU 2009-13, a portion of revenue for the Niobe, Odyssey Vision, Odyssey Cinema, and Vdrive systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Beginning in the quarter ended March 31, 2010, revenue for Odyssey Vision Standard HD systems was recognized upon delivery due to the fact that third parties became qualified to perform installations. However, this change did not have a material impact on revenue recognition for the year ended December 31, 2010. Beginning in the quarter ended June 30, 2010, revenue for Odyssey Vision Quad systems was recognized upon delivery due to the fact that third parties became qualified to perform installations. This change resulted in additional revenue of $2.6 million and additional gross margin of $1.3 million during the year ended December 31, 2010. Beginning in the quarter ended December 31, 2010, revenue for Odyssey Cinema systems was recognized upon delivery due to the fact that third parties became qualified to perform installations. This change resulted in additional revenue of $0.7 million and additional $0.4 million in gross margin. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. However, the Company may deliver systems to a non-hospital site at the customer’s request as outlined in the terms and conditions of the sales agreement, in which case the Company evaluates whether the substance of the transaction meets the delivery and performance requirements for revenue recognition under “bill and hold” guidance. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Research and Development	Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic alliances under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.
Share-Based Compensation	Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date. The Company utilizes the Black-Scholes valuation model to determine the fair value of share-based payments at the date of grant with the following inputs: 1) expected dividend rate of 0%; 2) expected volatility of 50-151% based on the Company’s historical volatility; 3) risk-free interest rate based on the Treasury yield on the date of grant and; 4) expected term for grants using the simplified method which results in an expected term ranging from 3.75 to 6.25 years. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments.
Net Earnings (Loss) Per Common Share	Net Loss per Common Share Basic loss per common share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the loss for the period by the weighted average number of common and common equivalent shares outstanding during the period. In addition, the application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable because the Company’s unearned restricted shares do not contractually participate in its losses. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. On July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock. The net loss per common share, shares outstanding, and weighted average shares outstanding reported in the financial statements and notes to the financial statements for the periods ending December 31, 2012, 2011, and 2010 are presented on a post-split basis. See Note 11 for additional discussion of the reverse stock split. As of December 31, 2012, the Company had 373,899 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $43.90 per share and 6,099,476 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $9.98 per share. The Company had a weighted average of 99,087 unearned restricted shares outstanding for the period ended December 31, 2012.
Income Tax	Income Taxes In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized.
Product Warranty Provisions	Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.
Patent Costs	Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
Reclassifications	Reclassifications Common stock and additional paid-in capital in the prior year’s financial statements have been reclassified to reflect the one-for-ten reverse stock split effected on July 10, 2012. Refer to Note 11 for additional discussion of the reverse stock split.

Inventory (Tables)

12 Months Ended

Dec. 31, 2012

Inventory [Abstract]

Schedule Of Inventory


	December 31,	December 31,
	2012	2011

Raw materials	$ 3,303,053	$ 2,264,603
Work in process	65,546	131,980
Finished goods	1,802,281	3,790,625
Reserve for obsolescence	(72,639)	(151,157)
Total inventory	$ 5,098,241	$ 6,036,051

Prepaid Expenses And Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2012

Prepaid Expenses And Other Current Assets [Abstract]

Schedule Of Prepaid Expenses And Other Current Assets



	December 31, 2012	December 31, 2011

Prepaid expenses	$ 330,756	$ 460,297
Deferred cost of revenue	527,725	289,312
Derivative asset	1,736	-
Deferred Financing	1,590,916	1,647,435
Other assets	1,040,934	684,440
Total prepaid expenses and other current assets	$ 3,492,067	$ 3,081,484

Property And Equipment (Tables)

12 Months Ended

Dec. 31, 2012

Property And Equipment [Abstract]

Schedule Of Property And Equipment


	December 31,	December 31,
	2012	2011

Equipment	$ 8,762,041	$ 8,977,623
Equipment held for lease	303,412	547,416
Leasehold improvements	2,328,381	2,473,880
	11,393,834	11,998,919
Less: Accumulated depreciation	(9,251,911)	(8,675,063)
Net property and equipment	$ 2,141,923	$ 3,323,856

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2012

Accrued Liabilities [Abstract]

Schedule Of Accrued Liabilities


	December 31,	December 31,
	2012	2011

Accrued salaries, bonus, and benefits	$ 2,123,167	$ 3,229,382
Accrued research and development	89,654	27,044
Accrued legal and other professional fees	219,000	25,000
Other	2,929,989	2,421,740
Total accrued liabilities	$ 5,361,810	$ 5,703,166

Deferred Revenue (Tables)

12 Months Ended

Dec. 31, 2012

Deferred Revenue [Abstract]

Schedule Of Deferred Revenue


	December 31,	December 31,
	2012	2011

Product shipped, revenue deferred	$ 3,206,641	$ 2,001,160
Customer deposits	558,227	1,156,900
Deferred service and license fees	6,215,230	5,696,959
	9,980,098	8,855,019
Less: Long-term deferred revenue	(477,159)	(634,713)
Total current deferred revenue	$ 9,502,939	$ 8,220,306

Long-Term Debt And Credit Facilities (Tables)

12 Months Ended

Dec. 31, 2012

Long-Term Debt And Credit Facilities [Abstract]

Schedule Of Long-Term Debt Outstanding

	December 31, 2012		December 31, 2011
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Revolving line of credit, due June 2013	$ 7,253,017	$ 7,277,084	$ 15,290,510	$ 15,371,063
Term note, due December 2013	4,000,000	4,000,000	8,000,000	8,000,000
Healthcare Royalty Partners debt	16,248,075	16,248,075	15,173,342	15,173,342
Subordinated convertible debentures	1,588,134	1,588,134	-	-
Total debt	29,089,226	29,113,293	38,463,852	38,544,405
Less current maturities	(12,264,490)	(12,288,557)	(21,173,321)	(21,253,874)
Total long term debt	$ 16,824,736	$ 16,824,736	$ 17,290,531	$ 17,290,531

Contractual Principal Maturities Of Debt


2013	$	12,264,490
2014⁽¹⁾		10,097,285
2015		2,312,052
2016		2,710,351
2017		3,177,265
2018 and Beyond		5,064,649
	$	35,626,092	⁽²⁾

(1) Includes $6.5 million convertible debt discount related to debt maturing on May 7, 2014.
(2) Future principal payments of Biosense Webster advance based on estimated future royalties.

Lease Obligations (Tables)

12 Months Ended

Dec. 31, 2012

Lease Obligations [Abstract]

Future Minimum Lease Payments


		Operating
Year		Lease
2013	$	1,728,937
2014		1,731,904
2015		1,710,778
2016		2,194,791
2017		2,189,376
2018 and Beyond		2,186,668
Total minimum lease payments		11,742,454

Stockholder's Equity (Tables)

12 Months Ended

Dec. 31, 2012

Stockholders' Equity [Abstract]

Summary Of Reserved Shares Of Common Stock


	December 31,	December 31,
	2012	2011
Warrants	6,099,476	1,038,161
Stock award plans	131,464	36,469
Employee Stock Purchase Plan	0	10,415
	6,230,940	1,085,045

Summary Of The Option And Stock Appreciation Rights Activity

	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2011	562,733	$10.00 - $125.50	$ 48.53
Granted	12,048	$1.63 - $8.10	$ 4.32
Exercised	-	$0.00 - $0.00	-
Forfeited	(200,882)	$1.69 - $125.50	$ 54.51
Outstanding, December 31, 2012	373,899	$1.63 - $116.40	$ 43.90

Summary Of The Options And Stock Appreciation Rights Outstanding By Range Of Excercise Price


	Year Ended December 31, 2012
							Number of		Weighted
			Weighted		Weighted		Options		Average Exercise
	Options		Average		Average		Currently		Price Per Vested
Range of Exercise Prices	Outstanding		Remaining Life		Exercise Price		Exercisable		Share
$1.00 - $20.00		30,147		8.87 years	$	8.33		7,275	$	10.39
$20.01 - $50.00		264,239		5.04 years	$	38.79		180,383	$	39.53
$50.01 - $100.00		67,863		2.22 years	$	68.00		67,841	$	68.00
$100.01 - $150.00		11,650		3.78 years	$	112.05		11,650	$	112.05
		373,899		4.7 years	$	43.90		267,149	$	49.13

Summary Of The Restricted Share Grant Activity

	Number of Shares	Weighted Average Grant Date Fair Value per Share

Outstanding, December 31, 2011	52,659	$ 34.17
Granted	85,250	$ 8.00
Vested	(4,001)	$ 37.32
Forfeited	(65,365)	$ 14.05
Outstanding, December 31, 2012	68,543	$ 20.62

Summary Of The Restricted Stock Unit Activity

	Number of Restricted Shares Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2011	98,820	$ 10.89
Granted	509,272	$ 1.89
Vested	(29,919)	$ 10.89
Forfeited	(48,861)	$ 6.51

Outstanding, December 31, 2012	529,312	$ 2.64

Summary Of The Restricted Stock Outstanding

	Number of Shares

Time based restricted shares	9,458
Performance based restricted shares	59,085
Outstanding, December 31, 2012	68,543

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2012

Fair Value Measurements [Abstract]

Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets at December 31, 2012:
Cash equivalents	$	256,702	256,702	—	—
Derivative asset		1,736	—	—	1,736
Total assets at fair value	$	258,438	256,702	—	1,736
Liabilities at December 31, 2012:
Warrants issued December 29, 2008	$	71,581	—	—	71,581
Warrants issued May 10, 2012		2,347,902	—	—	2,347,902
Derivative liability		548,865	—	—	548,865
Total liabilities at fair value:	$	2,968,348	—	—	2,968,348
Assets at December 31, 2011:
Cash equivalents	$	55,629	55,629	—	—
Total assets at fair value	$	55,629	55,629	—	—
Liabilities at December 31, 2011:
Warrants issued December 29, 2008	$	125,415	—	—	125,415
Total liabilities at fair value:	$	125,415	—	—	125,415

Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities

	Derivative Asset	Total Assets	Warrants issued December 29, 2008	Warrants issued May 10, 2012		Derivative Liability		Total Liabilities
Balance at beginning of period⁽¹⁾	$ 18,508	$ 18,508	$ 125,415	$ 7,573,466	$ 3,476,134		$ 11,175,015
Settlements	-	-	-	-		(23,643)		(23,643)
Revaluation	(16,772)	(16,772)	(53,834)	(5,225,564)		(2,903,626)		(8,183,024)
Balance at end of period	$ 1,736	$ 1,736	$ 71,581	$ 2,347,902		$ 548,865		$ 2,968,348

⁽¹⁾The beginning of the period is December 31, 2011 for warrants issued December 29, 2008. The beginning of the period for the derivative asset, warrants issued May 10, 2012, and derivative liability is May 10, 2012.

- Definition

Tabular disclosure of the fair value measurement of assets and liabilities which includes [financial] instruments measured at fair value that are classified in stockholders' equity. Such assets and liabilities may be measured on a recurring or nonrecurring basis. The disclosures which may be required or desired include: (1) for assets and liabilities measured on a recurring basis, disclosure may include: (a) the fair value measurements at the reporting date; (b) the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3); (c) for fair value measurements using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (ii) purchases, sales, issuances, and settlements (net); (iii) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs); (d) the amount of the total gains or losses for the period in subparagraph (c) (i) above included in earnings (or changes in net assets) that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date and a description of where those unrealized gains or losses are reported in the statement of income (or activities); (e) the valuation technique(s) used to measure fair value and a discussion of changes in valuation techniques, if any, during the period and (2) for assets and liabilities that are measured at fair value on a nonrecurring basis (for example, impaired assets) disclosure may include, in addition to (a) above: (a) the reasons for the fair value measurements recorded; (b) the same as (b) above; (c) for fair value measurements using significant unobservable inputs (Level 3), a description of the inputs and the information used to develop the inputs; and (d) the valuation technique(s) used to measure fair value and a discussion of changes, if any, in the valuation technique(s) used to measure similar assets and/or liabilities in prior periods. Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 33
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 6
-Footnote 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19190-110258

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19279-110258

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

+ Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2012

Income Taxes [Abstract]

Schedule of Components of Income Tax Provision


	Year Ended December 31,
	2012			2011			2010
Deferred:
Federal	$	4,586,506		$	11,367,771		$	5,650,309
State and local		493,946			1,437,062			464,169
		5,080,452			12,804,833			6,114,478
Valuation allowance		(5,080,452	)		(12,804,833	)		(6,114,478	)
	$	—		$	—		$	—

Schedule of Reconciliation of Federal Income Tax Rate


	Year Ended December 31,
	2012		2011		2010
U.S. statutory income tax rate	34.0	%	34	%	34	%
State and local taxes, net of federal tax benefit	5.2	%	4.5	%	2.3	%
Permanent differences between book and tax and other	14.4	%	1.5	%	(5.6	)%
Valuation allowance	(53.6	)%	(40.0	)%	(30.7	)%
Effective income tax rate	0	%	0	%	0	%

Schedule of Deferred Tax Assets


	December 31,
	2012			2011
Current accruals	$	1,753,064		$	1,751,515
Depreciation and amortization		2,676,884			2,644,059
Deferred compensation		5,332,415			4,648,719
Net operating loss carryovers		127,477,179			123,114,797
Deferred tax assets		137,239,542			132,159,090
Valuation allowance		(137,239,542	)		(132,159,090	)
Net deferred tax assets	$	—		$	—

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2012

Net Loss Per Share [Abstract]

Computation Of Basic And Diluted EPS


	Year Ended December 31,
	2012		2011		2010
Numerator:
Numerator for basic EPS	$	(9,238,427)	$	(32,031,175)	$	(19,923,487)
Effect of dilutive securities:		—		—		—
Numerator for diluted EPS	$	(9,238,427)	$	(32,031,175)	$	(19,923,487)
Denominator:
Denominator for basic EPS—weighted average shares		6,944,928		5,482,627		5,052,200
Effect of dilutive securities:		—		—		—
Denominator for diluted EPS		6,944,928		5,482,627		5,052,200
Basic EPS	$	(1.33)	$	(5.84)	$	(3.94)
Diluted EPS	$	(1.33)	$	(5.84)	$	(3.94)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


	December 31,
	2012		2011		2010
Shares outstanding
Restricted shares		68,543		52,659		3,328
Shares issuable upon vesting/exercise of:
Options to purchase common stock		373,899		562,733		471,108
Restricted stock units		529,312		98,820		—
Warrants		6,099,476		1,038,161		1,038,161
		7,071,230		1,752,374		1,512,598

Product Warranty Provisions (Tables)

12 Months Ended

Dec. 31, 2012

Product Warranty Provisions [Abstract]

Schedule Of Accrued Warranty


	December 31, 2012		December 31, 2011
Warranty accrual, beginning of the fiscal year	$	691,832	$	469,837
Warranty expense incurred		650,367		762,872
Payments made		(688,726)		(540,877)
Warranty accrual, end of the fiscal year	$	653,473	$	691,832

Segment Information (Tables)

12 Months Ended

Dec. 31, 2012

Segment Information [Abstract]

Schedule of Revenue by Geographical Areas


	Year Ended December 31,
	2012		2011		2010
United States	$	27,034,200	$	23,947,048	$	28,840,803
International		19,528,234		18,040,384		25,210,434
Total	$	46,562,434	$	41,987,432	$	54,051,237

Quarterly Data (Tables)

12 Months Ended

Dec. 31, 2012

Quarterly Data (Unaudited) [Abstract]

Schedule of Quarterly Financial Information



								Basic			Diluted
								Loss Per			Loss Per
	Net Sales		Gross Profit		Net Loss			Share			Share
2012
First quarter	$	12,283,228	$	8,521,397	$	(5,812,912	)	$	(1.06	)	$	(1.06	)
Second quarter		10,512,898		7,252,820		2,806,427			0.42			0.32
Third quarter		11,561,399		8,074,578		(1,915,281	)		(0.25	)		(0.25	)
Fourth quarter		12,204,910		7,932,584		(4,316,661	)		(0.55	)		(0.55	)
2011
First quarter	$	10,224,704	$	7,219,725	$	(9,549,933	)	$	(1.75	)	$	(1.75	)
Second quarter		11,602,139		8,085,793		(9,694,685	)		(1.77	)		(1.77	)
Third quarter		8,544,014		5,886,760		(7,273,070	)		(1.33	)		(1.33	)
Fourth quarter		11,616,575		8,297,073		(5,513,487	)		(1.00	)		(1.00	)

Description Of Business (Details)	12 Months Ended
Description Of Business (Details)	Dec. 31, 2012 USD ($) item	Dec. 31, 2011 USD ($)
Description Of Business [Line Items]
Cumulative losses incurred from inception	$ (384,645,873)	$ (375,407,446)
Installed base \| item	74
Reduction in operating expenses	$ 19,000,000
Annual plan to rebalance and reduce operating expenses, percentage	31.00%
Scenario, Forecast [Member] \| Maximum [Member]
Description Of Business [Line Items]
Annual plan to rebalance and reduce operating expenses, percentage	20.00%
Scenario, Forecast [Member] \| Minimum [Member]
Description Of Business [Line Items]
Annual plan to rebalance and reduce operating expenses, percentage	15.00%

Summary Of Significant Accounting Policies (Narrative) (Details)		8 Months Ended	12 Months Ended
	Jul. 10, 2012 item	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($) shares	Dec. 31, 2010 USD ($) shares	Dec. 29, 2008 shares
Summary Of Significant Accounting Policies [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure		$ 256,702	$ 256,702	$ 55,629
Derivative asset		1,736	1,736
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Revaluation		(16,772)
Liabilities, Fair Value Disclosure		2,968,348	$ 2,968,348	125,415
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Revaluations		(8,183,024)		$ (3,416,383)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements
Number of shares converted \| shares
Convertible debentures
Stock options and stock appreciation rights \| shares		373,899	373,899
Warrants \| shares		6,099,476	6,099,476	1,038,161
Weighted average exercise price \| $ / shares		$ 43.90	$ 43.90
Weighted average exercise price of warrants or rights \| $ / shares		$ 9.98	$ 9.98
Revenue from major customer			2,452,034	1,899,158	6,074,479
Percentage revenue from major customer			5.00%	5.00%	11.00%
Reverse stock split \| item	10
Restricted Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Weighted average unearned restricted shares outstanding \| shares			99,087
Black-Scholes Model Used to Value Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Historical dividend rate			0.00%
Historical volatility, lower limit			50.00%
Historical volatility, upper limit			151.00%
Historical expected term, lower limit			3 years 9 months
Historical expected term, upper limit			6 years 3 months
Fair Value, Inputs, Level 3 [Member]
Summary Of Significant Accounting Policies [Line Items]
Derivative asset		$ 1,736	$ 1,736
Liabilities, Fair Value Disclosure		2,968,348	$ 2,968,348	$ 125,415
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements		$ (23,643)
Warrants \| shares						179,241

Inventory (Schedule Of Inventory) (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Inventory [Abstract]
Raw materials	$ 3,303,053	$ 2,264,603
Work in process	65,546	131,980
Finished goods	1,802,281	3,790,625
Reserve for obsolescence	(72,639)	(151,157)
Total inventory	$ 5,098,241	$ 6,036,051

- Definition

The amount of the valuation account as of the balance sheet date which reduces the carrying amount of inventory to net realizable value; takes into consideration such factors as market value, excessive quantities based on expected sales, technological obsolescence, and shrinkage. May also provide for estimated product returns or price concessions pertaining to product cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 4
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 4
-Paragraph 8, 9, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=6386940&loc=d3e100047-122729

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e24092-122690

+ Details

Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 330,756	$ 460,297
Deferred cost of revenue	527,725	289,312
Derivative asset	1,736
Deferred financing	1,590,916	1,647,435
Other assets	1,040,934	684,440
Total prepaid expenses and other current assets	$ 3,492,067	$ 3,081,484

Property And Equipment (Schedule Of Property And Equipment) (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Property And Equipment [Abstract]
Equipment	$ 8,762,041	$ 8,977,623
Equipment held for lease	303,412	547,416
Leasehold improvements	2,328,381	2,473,880
Gross property and equipment	11,393,834	11,998,919
Less: Accumulated depreciation	(9,251,911)	(8,675,063)
Net property and equipment	$ 2,141,923	$ 3,323,856

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References + Details

Intangible Assets (Details) - USD ($)		12 Months Ended
Intangible Assets (Details) - USD ($)	Jun. 04, 2010	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Intangible Assets [Abstract]
Total shares to exchange for intellectual property on agreement	45,000
Shares issued upon execution of agreement	20,000
Aggregate shares to be issued in annual installments on the first three anniversaries of the agreement	25,000
Total intangible assets, including those subject to execution of agreement		$ 3,700,000
Accumulated amortization		1,685,681	$ 1,385,849
Amortization Expense		299,833	$ 299,833	$ 230,459
Future Amortization Expense, Through July 2018		299,833
Future Amortization Expense, August 2018 Through May 2020		$ 166,500

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 2,123,167	$ 3,229,382
Accrued research and development	89,654	27,044
Accrued legal and other professional fees	219,000	25,000
Other	2,929,989	2,421,740
Total accrued liabilities	$ 5,361,810	$ 5,703,166

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Deferred Revenue (Schedule Of Deferred Revenue) (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 9,980,098	$ 8,855,019
Less: Long-term deferred revenue	(477,159)	(634,713)
Total current deferred revenue	9,502,939	8,220,306
Product Shipped, Revenue Deferred [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	3,206,641	2,001,160
Customer Deposits [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	558,227	1,156,900
Deferred Service And License Fees [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 6,215,230	$ 5,696,959

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Long-Term Debt And Credit Facilities (Narrative) (Details) $ / shares in Units, item in Millions		1 Months Ended				3 Months Ended	12 Months Ended
	May 10, 2012 USD ($)	May 31, 2012 USD ($) item $ / shares $ / item shares	Mar. 30, 2012 USD ($) $ / item shares	Nov. 30, 2011 USD ($)	Dec. 31, 2010 USD ($) $ / item shares	Dec. 31, 2012 USD ($) $ / item shares	Dec. 31, 2012 USD ($) $ / item shares	Dec. 31, 2011 USD ($) shares	Dec. 31, 2010 USD ($) $ / item shares	Sep. 30, 2012	May 01, 2012 USD ($) shares	Sep. 30, 2011 USD ($)	Nov. 30, 2010 USD ($) $ / item shares	Jul. 31, 2008 USD ($)	Jun. 30, 2007
Debt Instrument [Line Items]
Variable rate on interest												3.50%			1.00%
Warrants \| shares						6,099,476	6,099,476	1,038,161
Fair value of warrants issued						$ 71,581	$ 71,581
Paydown of the guarantees							7,000,000
Amount borrowed							2,500,000	$ 14,317,397
Research and development expenses, Biosense Webster							400,000	1,100,000	$ 600,000
Disposables, service and accessories revenue, Biosense Webster							3,200,000	$ 3,600,000	$ 3,900,000
Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Current borrowing capacity						7,700,000	7,700,000
Line of credit facility, amount outstanding						7,300,000	7,300,000
Line of credit facility, remaining borrowing capacity						400,000
Line of Credit Facility, Current Borrowing Capacity						7,700,000	7,700,000
Term Note [Member]
Debt Instrument [Line Items]
Warrants \| shares					11,111				11,111
Exercise price of warrants \| $ / item					36.00				36.00
Fair value of warrants issued					$ 228,332				$ 228,332
Term loan agreement, face value					10,000,000	2,000,000	2,000,000		10,000,000
Healthcare Royalty Partners debt [Member]
Debt Instrument [Line Items]
Amount borrowed				$ 15,000,000
Additional amount which may be borrowed				$ 5,000,000
Percentage of royalties entitled to				100.00%
Annual interest rate				16.00%
Additional amount borrowed							2,500,000
Subordinated Convertible Debentures [Member]
Debt Instrument [Line Items]
Warrants \| shares		2,500,000
Exercise price of warrants \| $ / item		3.361
Annual interest rate		8.00%
Proceeds from Convertible Debt		$ 8,500,000
Conversion price per share \| $ / shares		$ 3.361
Number of convertible shares \| item		2.5
Debt discount		$ 7,500,000
Fair value of warrants		4,100,000
Fair value of derivative liability		$ 3,500,000
Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Advance on royalty amounts														$ 18,000,000
2009 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 30,000,000				30,000,000
Accrued interest on facility, floor					7.00%
Guarantees From Stockholders [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 10,000,000				10,000,000				$ 10,000,000
Accrued interest on facility, floor					6.00%
Warrants \| shares													80,000
Exercise price of warrants \| $ / item													40.15
Fair value of warrants issued													$ 1,747,392
March 30, 2012 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 10,000,000
Decrease in maximum borrowing capacity			$ 3,333,333
Warrants \| shares			75,735
Exercise price of warrants \| $ / item			6.60
May 1, 2012 Agreement [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity											$ 10,000,000
Warrants \| shares											60,976
May 10, 2012 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 20,000,000
Current borrowing capacity	13,000,000
Paydown of the guarantees	7,000,000
Net proceeds from issuance of long-term debt	18,500,000
Line of Credit Facility, Current Borrowing Capacity	$ 13,000,000
March 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 3,000,000	$ 3,000,000
Warrants \| shares						113,636	113,636
Exercise price of warrants \| $ / item						1.98	1.98
September 2011 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity												$ 20,000,000
Principal Due 2013 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due					$ 4,000,000				4,000,000
Principal Due 2012 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due					4,000,000				4,000,000
Principal Due 2011 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due					$ 2,000,000				$ 2,000,000
Research And Development Expenses [Member] \| Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Advance on royalty amounts														8,000,000
Royalty Amounts [Member] \| Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Advance on royalty amounts														$ 10,000,000
Prime Rate Plus [Member] \| Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Variable rate on interest														0.75%
Prime Rate Plus [Member] \| 2009 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Variable rate on interest					1.75%				1.75%
Prime Rate Plus [Member] \| Guarantees From Stockholders [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Variable rate on interest					0.50%				0.50%
Prime Rate Plus [Member] \| September 2011 Amendment [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Variable rate on interest						5.50%	5.50%			5.50%
Prime Rate Plus [Member] \| 2010 Amendment To Loan Agreement [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Variable rate on interest					3.50%				3.50%

Long-Term Debt And Credit Facilities (Schedule Of Long-Term Debt Outstanding) (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Debt Instrument [Line Items]
Total debt, Carrying Amount	$ 29,089,226	$ 38,463,852
Total debt, Estimated Fair Value	29,113,293	38,544,405
Less current maturities, Carrying Amount	(12,264,490)	(21,173,321)
Less current maturities, Estimated Fair Value	(12,288,557)	(21,253,874)
Total long term debt, Carrying Amount	16,824,736	17,290,531
Total long term debt, Estimated Fair Value	16,824,736	17,290,531
Revolving Credit Agreement, Due June 2013 [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount	7,253,017	15,290,510
Total debt, Estimated Fair Value	7,277,084	15,371,063
Term Note, Due December 2013 [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount	4,000,000	8,000,000
Total debt, Estimated Fair Value	4,000,000	8,000,000
Healthcare Royalty Partners debt [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount	16,248,075	15,173,342
Total debt, Estimated Fair Value	16,248,075	$ 15,173,342
Subordinated Convertible Debentures [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount	1,588,134
Total debt, Estimated Fair Value	$ 1,588,134

Long-Term Debt And Credit Facilities (Contractual Principal Maturities Of Debt) (Details) - USD ($)

Dec. 31, 2012

Dec. 31, 2011

Maturities of Long-term Debt [Abstract]

2013

$ 12,264,490

$ 21,173,321

2014

^[1]

10,097,285

2,312,052

2,710,351

3,177,265

5,064,649

^[2]

$ 35,626,092

[1]	Includes $6.5 million convertible debt discount related to debt maturing on May 7, 2014
[2]	Future principal payments of Biosense Webster advance based on estimated future royalties

Lease Obligations (Narrative) (Details) - USD ($)	12 Months Ended
Lease Obligations (Narrative) (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Lease Obligations [Abstract]
Rent Expense	$ 1,697,153	$ 1,711,647	$ 1,548,869

Lease Obligations (Schedule of Future Minimum Lease Payments) (Details)	Dec. 31, 2012 USD ($)
Lease Obligations [Abstract]
2013	$ 1,728,937
2014	1,731,904
2015	1,710,778
2016	2,194,791
2017	2,189,376
2018 and Beyond	2,186,668
Total minimum lease payments	$ 11,742,454

Stockholders' Equity (Narrative) (Details)		1 Months Ended		12 Months Ended
Stockholders' Equity (Narrative) (Details)	Jul. 10, 2012 item shares	May 31, 2012 $ / shares $ / item shares	Nov. 30, 2010 USD ($) $ / shares $ / item shares	Dec. 31, 2012 USD ($) yr $ / shares shares	Dec. 31, 2011 USD ($) $ / shares shares	Dec. 31, 2010 USD ($) $ / item shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued in public offering, shares			460,000
Stock issued in public offering, per share \| $ / shares			$ 36.50
Stock issued in public offering, value \| $			$ 15,500,000	$ 10,411,675		$ 20,037,506
Reverse stock split \| item	10
Common stock outstanding				8,018,615	5,543,157
Common stock authorized				300,000,000
Common stock authorized due to Amendment				300,000,000
Common stock par value \| $ / shares				$ 0.001	$ 0.001
Net proceeds from sale of securities \| $				$ 9,100,000
Paydown of the guarantees \| $				$ 7,000,000
Remaining shares of Company's common stock to provide for current and future grants under its various equity plans				131,464	36,469
Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees \| $				$ 5,900,000
Estimated forfeitures \| $				$ 3,300,000
Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees, period of amortization, in years \| yr				4
Number of options/SARs, outstanding, December 31, 2012				373,899
Weighted average exercise price per share, granted \| $ / shares				$ 4.32
Weighted average remaining life \| yr				4.7
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price \| $ / shares				$ 49.13
Weighted average exercise price per vested share \| $ / shares				$ 49.13
Number of options currently exercisable				267,149
Weighted average remaining life of vested options outstanding \| yr				4.0
Options and stock appreciation rights in-the-money				6,125
Intrinsic value of options and stock appreciation rights outstanding \| $				$ 5,298
Closing stock price \| $ / shares				$ 2.55
Exercise of stock options, shares				0
Exercise of stock options, value \| $				$ 0	$ 7,202	$ 460,500
Intrinsic value of restricted shares outstanding \| $				100,000
Intrinsic value of restricted stock units outstanding \| $				1,300,000
Intrinsic value of vested restricted shares \| $				0
Intrinsic value of vested restricted stock units \| $				100,000
Reduction of share based compensation \| $				$ (1,200,000)	$ (500,000)
Shares originally reserved for under Employee Stock Purchase Plan				25,000
Stock issued under Employee Stock Purchase Plan				24,901
Percentage of compensation eligible employees can use to purchase common stock, maximum				15.00%
Compensation amount eligible employees can use to purcahse common stock, maximum \| $				$ 25,000
Percentage of fair value eligible employees can purchase common stock				95.00%
Warrants				6,099,476	1,038,161
Warrants exercised				0	0	0
Pre-Stock Split [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding	78,000,000
Post-Stock Split [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding				7,800,000
Shares sold in private placement		2,170,000
Share price of shares sold in private placement \| $ / item		3.361
Warrants sold in private placement		2,170,000
Share price of warants sold in private placement \| $ / shares		$ 1.25
Exercise price of warrants \| $ / item		3.361
Revolving Line Of Credit [Member] \| Guarantees From Stockholders [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants \| $ / item			40.15
Warrants			80,000
Term Note [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants \| $ / item						36.00
Warrants						11,111
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized				100,000,000

Stockholders' Equity (Summary Of Reserved Shares Of Common Stock) (Details) - shares	Dec. 31, 2012	Dec. 31, 2011
Stockholders' Equity [Abstract]
Warrants	6,099,476	1,038,161
Stock award plans	131,464	36,469
Employee Stock Purchase Plan	0	10,415
Total Reserved Shares of Common Stock	6,230,940	1,085,045

Stockholders' Equity (Summary Of The Option And Stock Appreciation Rights Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Exercised	0
Number of options/SARs, outstanding, December 31, 2012	373,899
Weighted average exercise price per share, granted	$ 4.32
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012	$ 43.90
Range of Exercise Price, Lower limit		$ 10.00
$10.00 - $125.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2011	562,733
Number of options/SARs, outstanding, December 31, 2012		562,733
Weighted Average Exercise Price per Share, Outstanding, December 31, 2011	$ 48.53
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012		$ 48.53
Range of Exercise Price, Lower limit		10.00
Range of Exercise Price, Upper limit		$ 125.50
$1.63 - $8.10 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Granted	12,048
Weighted average exercise price per share, granted	$ 4.32
Range of Exercise Price, Lower limit	1.63
Range of Exercise Price, Upper limit	$ 8.10
$0.00 - $0.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Exercised
Weighted Average Exercise Price per Share, Exercised
Range of Exercise Price, Lower limit	0.00
Range of Exercise Price, Upper limit	$ 0.00
$1.69 - $125.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Forfeited	(200,882)
Weighted Average Exercise Price per Share, Forfeited	$ 54.51
Range of Exercise Price, Lower limit	1.69
Range of Exercise Price, Upper limit	$ 125.50
$1.63 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options/SARs, outstanding, December 31, 2012	373,899
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012	$ 43.90
Range of Exercise Price, Lower limit	1.63
Range of Exercise Price, Upper limit	$ 116.40

Stockholders' Equity (Summary Of The Option And Stock Appreciation Rights Outstanding) (Details)	12 Months Ended
	Dec. 31, 2012 yr $ / shares shares	Dec. 31, 2011 $ / shares
Range of Exercise Price, Lower limit		$ 10.00
Number of options/SARs, outstanding, December 31, 2012 \| shares	373,899
Weighted average remaining life \| yr	4.7
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012	$ 43.90
Number of options currently exercisable \| shares	267,149
Weighted average exercise price per vested share	$ 49.13
$1.00 - $20.00 [Member]
Range of Exercise Price, Lower limit	1.00
Range of Exercise Price, Upper limit	$ 20.00
Number of options/SARs, outstanding, December 31, 2012 \| shares	30,147
Weighted average remaining life \| yr	8.87
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012	$ 8.33
Number of options currently exercisable \| shares	7,275
Weighted average exercise price per vested share	$ 10.39
$20.01 - $50.00 [Member]
Range of Exercise Price, Lower limit	20.01
Range of Exercise Price, Upper limit	$ 50.00
Number of options/SARs, outstanding, December 31, 2012 \| shares	264,239
Weighted average remaining life \| yr	5.04
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012	$ 38.79
Number of options currently exercisable \| shares	180,383
Weighted average exercise price per vested share	$ 39.53
$50.01 - $100.00 [Member]
Range of Exercise Price, Lower limit	50.01
Range of Exercise Price, Upper limit	$ 100.00
Number of options/SARs, outstanding, December 31, 2012 \| shares	67,863
Weighted average remaining life \| yr	2.22
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012	$ 68.00
Number of options currently exercisable \| shares	67,841
Weighted average exercise price per vested share	$ 68.00
$100.01 - $150.00 [Member]
Range of Exercise Price, Lower limit	100.01
Range of Exercise Price, Upper limit	$ 150.00
Number of options/SARs, outstanding, December 31, 2012 \| shares	11,650
Weighted average remaining life \| yr	3.78
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012	$ 112.05
Number of options currently exercisable \| shares	11,650
Weighted average exercise price per vested share	$ 112.05

Stockholders' Equity (Summary Of The Restricted Share Grant Activity) (Details) - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2012 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, December 31, 2011 \| shares	52,659
Number of Shares, Granted \| shares	85,250
Number of Shares, Vested \| shares	(4,001)
Number of Shares, Forfeited \| shares	(65,365)
Number of Shares, Outstanding, December 31, 2012 \| shares	68,543
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2011 \| $ / shares	$ 34.17
Weighted Average Grant Date Fair Value per Share/Unit, Granted \| $ / shares	8.00
Weighted Average Grant Date Fair Value per Share/Unit, Vested \| $ / shares	37.32
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited \| $ / shares	14.05
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2012 \| $ / shares	$ 20.62

Stockholders' Equity (Summary Of The Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2012 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, December 31, 2011 \| shares	98,820
Number of Shares, Granted \| shares	509,272
Number of Shares, Vested \| shares	(29,919)
Number of Shares, Forfeited \| shares	(48,861)
Number of Shares, Outstanding, December 31, 2012 \| shares	529,312
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2011 \| $ / shares	$ 10.89
Weighted Average Grant Date Fair Value per Share/Unit, Granted \| $ / shares	1.89
Weighted Average Grant Date Fair Value per Share/Unit, Vested \| $ / shares	10.89
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited \| $ / shares	6.51
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2012 \| $ / shares	$ 2.64

Stockholders' Equity (Summary Of The Restricted Stock Outstanding) (Details) - Restricted Stock [Member] - shares	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	68,543	52,659
Time Based Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	9,458
Performance Based Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	59,085

Fair Value Measurements (Narrative) (Details)		12 Months Ended
Fair Value Measurements (Narrative) (Details)	May 10, 2012 USD ($) $ / shares $ / item	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($) shares	Dec. 29, 2008 shares
Fair Value Measurements [Line Items]
Cash equivalents invested in money market funds		$ 256,702	$ 55,629
Issued warrants to purchase shares of common stock \| shares		6,099,476	1,038,161
Fair value of warrants issued		$ 71,581
Closing stock price \| $ / shares		$ 2.55
Mandatory conversion minimum per Debentures agreement	$ 2,500,000
Common Stock Closes Above $15.00 [Member]
Fair Value Measurements [Line Items]
Mandatory conversion percentage per Debentures agreement	50.00%
Share price which determines conversion per Debentures agreement \| $ / item	15.00
Common Stock Closes Above $20.00 [Member]
Fair Value Measurements [Line Items]
Mandatory conversion percentage per Debentures agreement	100.00%
Share price which determines conversion per Debentures agreement \| $ / item	20.00
Number of consecutive trading days required at stock price	20 days
Black-Scholes Model Used to Value Warrants [Member]
Fair Value Measurements [Line Items]
Dividend yield		0.00%
Volatility rate		116.49%
Risk-free interest rate		0.36%
Expected life		1 year 6 months
Monte-Carlo Simulation Used To Value Derivative Assets And Liabilities [Member]
Fair Value Measurements [Line Items]
Volatility rate	80.00%	85.00%
Risk-free interest rate	1.035%	0.802%
Closing stock price \| $ / shares	$ 3.4130	$ 2.55
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements [Line Items]
Issued warrants to purchase shares of common stock \| shares				179,241

Fair Value Measurements (Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level) (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 256,702	$ 55,629
Derivative asset	1,736
Total Assets at Fair Value	258,438	55,629
Fair value of warrants issued	71,581
Derivative liability	548,865
Total Liabilities at Fair Value	2,968,348	125,415
Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	71,581	125,415
Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	2,347,902
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	256,702	55,629
Total Assets at Fair Value	256,702	55,629
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Derivative asset
Total Assets at Fair Value
Derivative liability
Total Liabilities at Fair Value
Fair Value, Inputs, Level 2 [Member] \| Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued
Fair Value, Inputs, Level 2 [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	1,736
Total Assets at Fair Value	1,736
Derivative liability	548,865
Total Liabilities at Fair Value	2,968,348	125,415
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	71,581	$ 125,415
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	$ 2,347,902

Fair Value Measurements (Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities) (Details) - USD ($)

8 Months Ended

12 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Assets, Balance at beginning of period

^[1]

$ 18,508

Assets, Settlements

Assets, Revaluation

(16,772)

Assets, Balance at end of period

1,736

$ 1,736

Liabilities, Balance at beginning of period

^[1]

11,175,015

Liabilities, Settlements

(23,643)

Liabilities, Revaluations

(8,183,024)

$ (3,416,383)

Liabilities, Balance at end of period

2,968,348

Warrants Issued December 29, 2008 [Member]

Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Liabilities, Balance at beginning of period

^[1]

125,415

Liabilities, Settlements

Liabilities, Revaluations

(53,834)

Liabilities, Balance at end of period

71,581

$ 125,415

^[1]

Warrants Issued May 10, 2012 [Member]

Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Liabilities, Balance at beginning of period

^[1]

7,573,466

Liabilities, Revaluations

(5,225,564)

Liabilities, Balance at end of period

2,347,902

Derivative Liability [Member]

Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Liabilities, Balance at beginning of period

^[1]

3,476,134

Liabilities, Settlements

(23,643)

Liabilities, Revaluations

(2,903,626)

Liabilities, Balance at end of period

548,865

Derivative Asset [Member]

Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Assets, Balance at beginning of period

^[1]

18,508

Assets, Settlements

Assets, Revaluation

(16,772)

Assets, Balance at end of period

$ 1,736

[1]	The beginning of the period is December 31, 2011 for warrants issued December 29, 2008. The beginning of the period for the derivative asset, warrants issued May 10, 2012, and derivative liability is May 10, 2012.

Income Taxes (Narrative) (Details)	Dec. 31, 2012 USD ($)
Income Taxes [Abstract]
Operating Loss Carryforwards	$ 351,000,000
State Operating Loss Carryforwards	$ 8,400,000

Income Taxes (Provision For Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Taxes [Abstract]
Federal	$ 4,586,506	$ 11,367,771	$ 5,650,309
State and local	493,946	1,437,062	464,169
Deferred Income Tax Expense (Benefit), Total	5,080,452	12,804,833	6,114,478
Valuation allowance	(5,080,452)	(12,804,833)	(6,114,478)
Income Tax Benefit

- Definition

The component of total income tax expense for the period comprised of the increase (decrease) during the period in the entity's domestic deferred tax assets and liabilities attributable to continuing operations as determined by applying the provisions of the federally enacted tax law.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 8, 16, 17, 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

+ Details

- Definition

The component of total income tax expense for the period comprised of the increase (decrease) in the entity's state and local deferred tax assets and liabilities attributable to continuing operations as determined by applying the provisions of the applicable enacted tax laws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 8, 16, 17, 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Income Taxes (Schedule of Reconciliation of Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Taxes [Abstract]
U.S. statutory income tax rate	34.00%	34.00%	34.00%
State and local taxes, net of federal tax benefit	5.20%	4.50%	2.30%
Permanent differences between book and tax and other	14.40%	1.50%	(5.60%)
Valuation allowance	53.60%	40.00%	30.70%
Effective income tax rate	0.00%	0.00%	0.00%

Income Taxes (Schedule of Deferred Tax Asset) (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Abstract]
Current accruals	$ 1,753,064	$ 1,751,515
Depreciation and amortization	2,676,884	2,644,059
Deferred compensation	5,332,415	4,648,719
Net operating loss carryovers	127,477,179	123,114,797
Deferred Tax Assets, Gross, Total	137,239,542	132,159,090
Valuation allowance	(137,239,542)	(132,159,090)
Deferred Tax Assets, Net, Total

- Definition

The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from employee compensation costs, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.

+ References + Details

- Definition

The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from currently nondeductible expenses in accrued liabilities, which can only be deducted for tax purposes when such items are actually incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.

+ References + Details

Net Loss Per Share (Computation of Basic and Diluted EPS) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Net Loss Per Share [Abstract]
Numerator for basic EPS	$ (4,316,661)	$ (1,915,281)	$ 2,806,427	$ (5,812,912)	$ (5,513,487)	$ (7,273,070)	$ (9,694,685)	$ (9,549,933)	$ (9,238,427)	$ (32,031,175)	$ (19,923,487)
Convertible debentures
Numerator for diluted EPS									$ (9,238,427)	$ (32,031,175)	$ (19,923,487)
Denominator for basic EPS - weighted average shares									6,944,928	5,482,627	5,052,200
Convertible debentures
Denominator for diluted EPS									6,944,928	5,482,627	5,052,200
Basic EPS	$ (0.55)	$ (0.25)	$ 0.42	$ (1.06)	$ (1.00)	$ (1.33)	$ (1.77)	$ (1.75)	$ (1.33)	$ (5.84)	$ (3.94)
Diluted EPS	$ (0.55)	$ (0.25)	$ 0.32	$ (1.06)	$ (1.00)	$ (1.33)	$ (1.77)	$ (1.75)	$ (1.33)	$ (5.84)	$ (3.94)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 20

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 7
-Paragraph 18

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 19

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References + Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1448-109256

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Net Loss Per Share (Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,071,230	1,752,374	1,512,598
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	68,543	52,659	3,328
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	373,899	562,733	471,108
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	529,312	98,820
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,099,476	1,038,161	1,038,161

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Employee Benefit Plan (Details) - USD ($)	12 Months Ended
Employee Benefit Plan (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Empoyee Benefit Plan [Abstract]
Maximum Company Match Of Participant Contribution Of Eligible Compensation	3.00%
Defined Contribution Plan, Cost Recognized	$ 8,595	$ 395,633	$ 414,765

Product Warranty Provisions (Schedule Of Accrued Warranty) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Product Warrantie Provisions [Abstract]
Warranty accrual, beginning of the fiscal year	$ 691,832	$ 469,837
Warranty expense incurred	650,367	762,872
Payments made	(688,726)	(540,877)
Warranty accrual, end of the fiscal year	$ 653,473	$ 691,832

Commitments And Contingencies (Details) $ in Millions	Dec. 31, 2012 USD ($)
Commitments And Contingencies [Abstract]
Letter of credit	$ 0.1

Segment Information (Details) - USD ($)	12 Months Ended
Segment Information (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Segment Information [Abstract]
United States	$ 27,034,200	$ 23,947,048	$ 28,840,803
International	19,528,234	18,040,384	25,210,434
Total revenue	$ 46,562,434	$ 41,987,432	$ 54,051,237

Quarterly Data (Details) - USD ($)	3 Months Ended								12 Months Ended
Quarterly Data (Details) - USD ($)	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Quarterly Data (Unaudited) [Abstract]
Revenue, Net	$ 12,204,910	$ 11,561,399	$ 10,512,898	$ 12,283,228	$ 11,616,575	$ 8,544,014	$ 11,602,139	$ 10,224,704
Gross Profit	7,932,584	8,074,578	7,252,820	8,521,397	8,297,073	5,886,760	8,085,793	7,219,725	$ 31,781,379	$ 29,489,351	$ 38,486,550
Net Loss	$ (4,316,661)	$ (1,915,281)	$ 2,806,427	$ (5,812,912)	$ (5,513,487)	$ (7,273,070)	$ (9,694,685)	$ (9,549,933)	$ (9,238,427)	$ (32,031,175)	$ (19,923,487)
Basic EPS	$ (0.55)	$ (0.25)	$ 0.42	$ (1.06)	$ (1.00)	$ (1.33)	$ (1.77)	$ (1.75)	$ (1.33)	$ (5.84)	$ (3.94)
Diluted EPS	$ (0.55)	$ (0.25)	$ 0.32	$ (1.06)	$ (1.00)	$ (1.33)	$ (1.77)	$ (1.75)	$ (1.33)	$ (5.84)	$ (3.94)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details